51
|
Fan Y, Zhou X. Application of the Plan-Do-Check-Action Cycle in Reducing the Incidence of Forearm Hematoma in Patients After Transradial Artery Percutaneous Coronary Interventions. J Multidiscip Healthc 2025; 18:1183-1189. [PMID: 40035030 PMCID: PMC11873013 DOI: 10.2147/jmdh.s511825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2024] [Accepted: 02/18/2025] [Indexed: 03/05/2025] Open
Abstract
Background Transradial puncture has the advantages of significantly fewer complications, less patient pain, shorter hospital stays, and reduced hospital costs, but it tends to cause forearm hematoma, so reducing the rate of forearm hematoma is imperative. This study assessed the value of the plan-do-check-act (PDCA) cycle in standardizing nursing management in reduce the incidence of forearm hematoma in patients after transradial artery Percotaneous Coronary Intervention(PCI). Methods This study was conducted on 260 patients with acute myocardial infarction admitted to our hospital between January 2022 and June 2022 who underwent coronary intervention. The subjects were divided into control-group (n=130) and observation-group (n=130) in accordance with their admission time. The control-group received routine nursing care; and the observation-group, was applied with PDCA nursing management in addition to conventional treatment. Results The incidence of forearm hematoma in patients after radial artery PCI decreased from 24.62% to 8.46% (P < 0.05). Conclusion The PDCA cycle management model was effective in reducing the incidence of forearm hematoma without increasing adverse patient outcomes.
Collapse
Affiliation(s)
- Yanqiu Fan
- Department of Cardiology, Jinhu County People’s Hospital, Huaian City, People’s Republic of China
| | - Xiaoyan Zhou
- Department of Cardiology, Jinhu County People’s Hospital, Huaian City, People’s Republic of China
| |
Collapse
|
52
|
Mo B, Ding Y, Ji Q. NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol 2025; 16:1550226. [PMID: 40079000 PMCID: PMC11896874 DOI: 10.3389/fimmu.2025.1550226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2024] [Accepted: 02/11/2025] [Indexed: 03/14/2025] Open
Abstract
Cardiovascular disease (CVD) continues to be the leading cause of mortality worldwide. The nucleotide oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is involved in numerous types of CVD. As part of innate immunity, the NLRP3 inflammasome plays a vital role, requiring priming and activation signals to trigger inflammation. The NLRP3 inflammasome leads both to the release of IL-1 family cytokines and to a distinct form of programmed cell death called pyroptosis. Inflammation related to CVD has been extensively investigated in relation to the NLRP3 inflammasome. In this review, we describe the pathways triggering NLRP3 priming and activation and discuss its pathogenic effects on CVD. This study also provides an overview of potential therapeutic approaches targeting the NLRP3 inflammasome.
Collapse
Affiliation(s)
- Binhai Mo
- People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
| | - Yudi Ding
- First People’s Hospital of Nanning, Nanning, Guangxi, China
| | - Qingwei Ji
- People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
| |
Collapse
|
53
|
Biesiekierska M, Strigini M, Śliwińska A, Pirola L, Balcerczyk A. The Impact of Ketogenic Nutrition on Obesity and Metabolic Health: Mechanisms and Clinical Implications. Nutr Rev 2025:nuaf010. [PMID: 40036324 DOI: 10.1093/nutrit/nuaf010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2025] Open
Abstract
The ketogenic diet (KD) has recently gained increasing popularity. This high-fat, adequate-protein, and carbohydrate-poor eating pattern leads to nutritional ketosis. The KD has long been known for its antidiabetic and antiepileptic effects and has been used therapeutically in these contexts. Recently, the KD, due to its effectiveness in inducing weight loss, has also been proposed as a possible approach to treat obesity. Likewise, a KD is currently explored as a supporting element in the treatment of obesity-associated metabolic disorders and certain forms of cancer. Here, we discuss the metabolic and biochemical mechanisms at play during the shift of metabolism to fatty acids and fatty acid-derived ketone bodies as main fuel molecules, in the substitution of carbohydrates, in ketogenic nutrition. Different sources of ketone bodies and KDs as alternatives to glucose and carbohydrates as main energy substrates are discussed, together with an attempt to weigh the benefits and risks posed by the chronic use of a KD in the context of weight loss, and also considering the molecular effects that ketone bodies exert on metabolism and on the endocrine system.
Collapse
Affiliation(s)
- Marta Biesiekierska
- Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland
| | - Maura Strigini
- University Jean Monnet Saint-Etienne, INSERM, Mines Saint Etienne, SAINBIOSE U1059, F-42023 Saint-Etienne, France
| | - Agnieszka Śliwińska
- Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland
| | - Luciano Pirola
- INSERM Unit 1060, CarMeN Laboratory, Lyon 1 University, F-69495 Pierre Bénite, France
| | - Aneta Balcerczyk
- Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland
| |
Collapse
|
54
|
Gorjipour F, Bohloolighashghaei S, Sotoudeheian M, Pazoki Toroudi H. Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions. Hum Cell 2025; 38:61. [PMID: 39998714 DOI: 10.1007/s13577-025-01190-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2024] [Accepted: 02/17/2025] [Indexed: 02/27/2025]
Abstract
Heart failure is known as the leading cause of mortality and morbidity in adults, not only in USA but worldwide. Since the world's population is aging, the burden of cardiovascular disorders is increasing. Mesenchymal stem/stromal cells (MSCs) from a patient's bone marrow or other tissues have been widely used as the primary source of stem cells for cellular cardiomyoplasty. The incongruencies that exist between various cell-therapy approaches for cardiac diseases could be attributed to variations in cell processing methods, quality of the process, and cell donors. Off-the-shelf preparations of MSCs, enabled by batch processing of the cells and controlled cell processing factories in regulated facilities, may offer opportunities to overcome these problems. In this study, for the first time, we focused on the fetal membranes and childbirth byproducts as a promising source of cells for regenerative medicine. While many studies have described the advantages of cells derived from these organs, their advantage as a source of younger cells has not been sufficiently covered by the literature. Thus, herein, we highlight challenges that may arise from the impairment of the regenerative capacity of MSCs due to donor age and how allograft cells from fetal adnexa can be a promising substitute for the aged patients' stem cells for myocardial regeneration. Moreover, obstacles to the use of off-the-shelf cell-therapy preparations in regenerative medicine are briefly summarized here.
Collapse
Affiliation(s)
- Fazel Gorjipour
- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | | | | | - Hamidreza Pazoki Toroudi
- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
- Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
55
|
Griva P, Griva V, Samara D, Talliou C, Panagouli K, Roungeris L. Central Venous Pressure as a Predictor of Acute Kidney Injury in Cardiac Surgery: A Systematic Review of Observational Studies. Diagnostics (Basel) 2025; 15:530. [PMID: 40075778 PMCID: PMC11898736 DOI: 10.3390/diagnostics15050530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2025] [Revised: 02/19/2025] [Accepted: 02/19/2025] [Indexed: 03/14/2025] Open
Abstract
Background/Objectives: Acute kidney injury (AKI) is a syndrome characterized by impaired kidney function, which is associated with reduced survival and increased morbidity. Central venous pressure (CVP) is a widely used hemodynamic parameter for assessing the volume status of patients and evaluating their response to fluid resuscitation. This systematic review aims to analyze various prospective and retrospective observational and controlled trials to determine the association between CVP and the risk of developing AKI in patients undergoing cardiac surgery. Additionally, it examines whether elevated CVP serves as an accurate predictor of AKI in this patient population. Methods: A systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, using PubMed as the primary database. The search focused on studies published after 2014 that included adult patients undergoing cardiac surgery with reported measurements of CVP and kidney function assessment. Studies conducted on animals, pediatric populations, those published before 2014, or in languages other than English were excluded from the review. Results: Through the analysis of 21 studies, a clear association between higher CVP and increased AKI risk emerged. The most critical CVP thresholds identified were 10 mmHg, 12 mmHg, 14 mmHg, and 20 mmHg, with risk increasing progressively beyond these values. CVP ≥ 10 mmHg was the most commonly reported cutoff for elevated AKI risk, showing 1.42 to 4.53 times increased odds. CVP ≥ 12 mmHg further amplified the risk, while CVP ≥ 14 mmHg was consistently associated with severe AKI and the need for RRT. The highest threshold (CVP ≥ 20 mmHg) showed the greatest risk escalation, linked to fluid overload, right heart failure, and mortality. Studies also suggest an optimal CVP range of 6-8 mmHg to minimize AKI incidence. Conclusions: Elevated CVP is an independent risk factor for the development of AKI in patients undergoing cardiac surgery. These findings suggest that CVP monitoring can play a significant role in predicting AKI and guiding perioperative management strategies.
Collapse
Affiliation(s)
- Panagiota Griva
- Department of Anesthesiology, University General Hospital Attikon, 12462 Athens, Greece;
| | - Vasiliki Griva
- Department of Internal Medicine, General Hospital of Athens “Sismanoglio”, 15126 Athens, Greece;
| | - Dimitra Samara
- School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece; (D.S.); (C.T.)
| | - Christina Talliou
- School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece; (D.S.); (C.T.)
| | - Konstantina Panagouli
- Department of Anesthesiology, University General Hospital Attikon, 12462 Athens, Greece;
| | - Loizos Roungeris
- Department of Anaesthesiology, Rea Maternity Hospital, 17564 Athens, Greece;
| |
Collapse
|
56
|
Peesh P, Blasco-Conesa MP, El Hamamy A, Khan R, Guzman GU, Honarpisheh P, Mohan EC, Goodman GW, Nguyen JN, Banerjee A, West BE, Ko KA, Korf JM, Tan C, Fan H, Colpo GD, Ahnstedt H, Couture L, Roh S, Kofler JK, Moruno-Manchon JF, Maniskas ME, Aronowski J, Ritzel RM, Lee J, Li J, Bryan RM, Chauhan A, Venna VR, McCullough LD, Ganesh BP. Benefits of equilibrium between microbiota- and host-derived ligands of the aryl hydrocarbon receptor after stroke in aged male mice. Nat Commun 2025; 16:1767. [PMID: 39971928 PMCID: PMC11839985 DOI: 10.1038/s41467-025-57014-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 02/04/2025] [Indexed: 02/21/2025] Open
Abstract
Recent studies have highlighted the crucial role of microglia (MG) and their interactions with the gut microbiome in post-stroke neuroinflammation. The activation of immunoregulatory pathways, including the aryl hydrocarbon receptor (AHR) pathway, is influenced by a dynamic balance of ligands derived from both the host and microbiota. This study aimed to investigate the association between stroke-induced dysbiosis and the resultant imbalance in AHR ligand sources (loss of microbiota-derived [indole-based] and increase of host-derived [kynurenine-based]) after stroke. Microbiota-derived AHR ligands decreased in human plasma and remained low for days following an ischemic stroke highlighting the translational significance. Transient-middle-cerebral-artery-occlusion was performed in aged wild-type and germ-free male mice. MG-AHR expression and activity increased in both in vivo and ex vivo stroke models. Germ-free mice showed altered neuroinflammation and antigen presentation while aged mice showed reduced infarct volume and neurological deficits following treatment with microbiota-derived AHR ligands after stroke. Restoring a balanced pool of host- and microbiota-derived AHR ligands may be beneficial after stroke and may represent a therapeutic target.
Collapse
Affiliation(s)
- Pedram Peesh
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
- The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
- Department of Neurosurgery, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Maria P Blasco-Conesa
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Ahmad El Hamamy
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Romeesa Khan
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Gary U Guzman
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Parisa Honarpisheh
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Eric C Mohan
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Grant W Goodman
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Justin N Nguyen
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Anik Banerjee
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
- The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Bryce E West
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Kyung Ae Ko
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Janelle M Korf
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
- The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Chunfeng Tan
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Huihui Fan
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Gabriela D Colpo
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Hilda Ahnstedt
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Lucy Couture
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Solji Roh
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Julia K Kofler
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Jose F Moruno-Manchon
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Michael E Maniskas
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Jaroslaw Aronowski
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Rodney M Ritzel
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Juneyoung Lee
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Jun Li
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Robert M Bryan
- Baylor College of Medicine, Department of Anesthesiology, Houston, TX, USA
| | - Anjali Chauhan
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Venugopal Reddy Venna
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA
| | - Louise D McCullough
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA.
| | - Bhanu Priya Ganesh
- Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, USA.
- The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
| |
Collapse
|
57
|
Ma H, Pei F, Han Z, Lian B, Liu G, Shi Y, Zhao Z. Sex-specific outcome after minimally invasive direct coronary artery bypass for single-vessel disease: a propensity score matching analysis. J Cardiothorac Surg 2025; 20:134. [PMID: 39972372 PMCID: PMC11837482 DOI: 10.1186/s13019-024-03163-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Accepted: 11/29/2024] [Indexed: 02/21/2025] Open
Abstract
OBJECTIVE To evaluate the influence of gender on surgical outcome in patients with single-vessel disease undergoing minimally invasive direct coronary artery bypass (MIDCAB). METHODS This retrospective, non-randomized study analyzed 471 patients who underwent MIDCAB between February 2012 and January 2021 through left lateral thoracic small incision in the Department of Cardiac Surgery of our hospital were selected. Data were collected on demographics, clinical characteristics, operative and postoperative outcomes, and follow-up mortality and morbidity. Propensity score matching (PSM) was used to match patients between the groups. RESULTS Before matching, female patients were older, had higher incidence of DM (40.2% Vs 27.3%, p = 0.013), higher LVEF (66.7 ± 8.0 Vs 63.6 ± 10.1, p<0.001) and smaller LVEDD (4.7 ± 0.5 Vs 5.1 ± 0.6, p = 0.001). After matching, the differences in baseline characteristics between both groups were eliminated. PS matching selected 103 matched pairs for final comparison. No significant differences were observed between both groups in terms of in-hospital mortality, the incidence of MACCE, incidence of perioperative MI, incidence of stroke, reoperation for bleeding. Female patients had longer length of stay compared to male patients (18.9 ± 14.3 Vs 15.5 ± 5.9, p = 0.027). CONCLUSION Female sex is not connected with higher risk of mortality or other major events in MIDCAB. Wound healing complications remain the leading attribute associated with female sex.
Collapse
Affiliation(s)
- Hao Ma
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Fengbo Pei
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Zengqiang Han
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Bo Lian
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Gang Liu
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Yi Shi
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China
| | - Zhou Zhao
- Department of Cardiac Surgery, Peking University People's Hospital, Beijing, 100044, PR China.
| |
Collapse
|
58
|
Purohit R, Appelgren-Gonzalez JP, Varas-Diaz G, Wang S, Hosiasson M, Covarrubias-Escudero F, Bhatt T. Feasibility of Smartphone-Based Exercise Training Integrated with Functional Electrical Stimulation After Stroke (SETS): A Preliminary Study. SENSORS (BASEL, SWITZERLAND) 2025; 25:1254. [PMID: 40006483 PMCID: PMC11861842 DOI: 10.3390/s25041254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2024] [Revised: 02/05/2025] [Accepted: 02/10/2025] [Indexed: 02/27/2025]
Abstract
One emerging method in home stroke rehabilitation is digital technology. However, existing approaches typically target one domain (e.g., upper limb). Moreover, existing interventions do not cater to older adults with stroke (OAwS), especially those with high motor impairment, who require adjunct therapeutic agents to independently perform challenging exercises. We examined the feasibility of Smartphone-based Exercise Training after Stroke (SETS) with Functional Electrical Stimulation (FES). A total of 12 participants (67 ± 5 years) with stroke (onset > 6 months) exhibiting moderate-to-high motor impairment (Chedoke McMaster Leg ≤ 4/7) underwent 6 weeks of multicomponent (gait, functional strength, dynamic balance) training integrated with FES to paretic lower limb muscles. Primary measures included safety and adherence. Secondary measures included motivation, acceptability and attitude, usability, and clinical measures of gait and balance function like the 10-Meter Walk Test and Mini-BESTest. Participants reported no adverse events and moderate-to-high adherence (84.17 ± 11.24%) and improvement (up to 40%) in motivation, acceptability, and attitude and system usability. Participants also showed pre-post improvements in all measures of gait and balance function (p < 0.05). Integrating SETS and FES is feasible and yields short-term gains in gait and balance function among OAwS. Future studies could validate our findings by examining its efficacy with control groups to identify the differential effects of SETS and FES.
Collapse
Affiliation(s)
- Rudri Purohit
- Department of Physical Therapy, University of Illinois at Chicago, Chicago, IL 60607, USA; (R.P.); (S.W.)
- PhD Program in Rehabilitation Sciences and Neuroscience, University of Illinois at Chicago, Chicago, IL 60607, USA
| | - Juan Pablo Appelgren-Gonzalez
- Translational Research Unit, Trainfes Center, Santiago 8760903, Chile; (J.P.A.-G.); (M.H.); (F.C.-E.)
- Biomedical Imaging Center, Pontifical Catholic University, Santiago 7820436, Chile
| | - Gonzalo Varas-Diaz
- Carrera de Kinesiología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile;
| | - Shuaijie Wang
- Department of Physical Therapy, University of Illinois at Chicago, Chicago, IL 60607, USA; (R.P.); (S.W.)
| | - Matias Hosiasson
- Translational Research Unit, Trainfes Center, Santiago 8760903, Chile; (J.P.A.-G.); (M.H.); (F.C.-E.)
| | - Felipe Covarrubias-Escudero
- Translational Research Unit, Trainfes Center, Santiago 8760903, Chile; (J.P.A.-G.); (M.H.); (F.C.-E.)
- Departamento de Kinesiología, Facultad de Arte y Educación Física, Universidad Metropolitana Ciencias de la Educación, Santiago 7760197, Chile
| | - Tanvi Bhatt
- Department of Physical Therapy, University of Illinois at Chicago, Chicago, IL 60607, USA; (R.P.); (S.W.)
| |
Collapse
|
59
|
Chen Y, Lai F, Xu H, He Y. Chinese herb pairs for cardiovascular and cerebrovascular diseases: Compatibility effects, pharmacological potential, clinical efficacy, and molecular mechanisms. JOURNAL OF ETHNOPHARMACOLOGY 2025; 347:119516. [PMID: 39978448 DOI: 10.1016/j.jep.2025.119516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2024] [Revised: 12/27/2024] [Accepted: 02/16/2025] [Indexed: 02/22/2025]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Cerebrovascular and cardiovascular diseases are pathophysiologically interconnected. In the past, researchers have mainly focused on developing one herbal medicine treatment. Single herb often fails to address the multifactorial pathology of these diseases. The pathogenesis and progression of the disease are complex, making the therapeutic effect of a single herb potentially limiting. Traditional Chinese medicine emphasizes herb pairs, which enhance therapeutic efficacy through synergistic interactions. AIM OF THE REVIEW This review focused on the mechanisms and potential clinical applications of Chinese herb pairs such as Astragali Radix-Carthami Flos, Salviae Miltiorrhizae Radix-Puerariae Lobatae Radix, Salviae Miltiorrhizae Radix-Chuanxiong Rhizoma, Salviae Miltiorrhizae Radix-Notoginseng Radix, Salviae Miltiorrhizae Radix-Carthami Flos, Astragali Radix-Angelicae Sinensis Radix, Notoginseng Radix-Carthami Flos, and Astragali Radix-Salviae Miltiorrhizae Radix, as well as provided a scientific basis for clinical applications of Chinese herb pairs. MATERIALS AND METHODS A systematic search and collection of studies on Chinese herb pairs in cardiovascular and cerebrovascular diseases was carried out using electronic databases such as PubMed, CNKI, Wan Fang Database, Baidu Scholar, and Web of Science. The keywords searched included Chinese herb pairs, cardiovascular disease, cerebrovascular disease, Astragali Radix, Salviae Miltiorrhizae Radix, Angelicae Sinensis Radix, Carthami Flos, Notoginseng Radix, and so on. RESULTS Studies revealed that the Chinese herb pairs had more beneficial effects than single herb and demonstrated a variety of roles in cardiovascular and cerebrovascular diseases. Preclinical studies indicated that Chinese herb pairs are more effective than single herb in treating cardiovascular and cerebrovascular diseases by modulating disease-related pathways and molecular targets. Further research is needed to fully explore their potential. The review also outlined the potential clinical applications of these Chinese herb pairs, highlighting their safety and efficacy. CONCLUSIONS Chinese herb pairs showed good promise as an alternative therapy for cardiovascular and cerebrovascular diseases due to their multi-component and multi-target characteristics. Consequently, further research was necessary to fully explore the potential of Chinese herb pairs in treating cardiovascular and cerebrovascular diseases, based on the current data.
Collapse
Affiliation(s)
- Yajie Chen
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
| | - Feifan Lai
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China; Zhejiang Key Laboratory of Chinese Medicine for Cardiovascular and Cerebrovascular Disease, China.
| | - Huaping Xu
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China; Zhejiang Key Laboratory of Chinese Medicine for Cardiovascular and Cerebrovascular Disease, China.
| | - Yu He
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China; Zhejiang Key Laboratory of Chinese Medicine for Cardiovascular and Cerebrovascular Disease, China.
| |
Collapse
|
60
|
Fiore G, Pinto G, Oppizzi M, Slavich M, Gaspardone C, Furlan F, Valsecchi D, Margonato A, Fragasso G. Incidence, predictors, and sex differences in acute coronary syndrome overdiagnosis among patients presenting to the emergency department with acute chest pain. J Cardiol 2025:S0914-5087(25)00055-3. [PMID: 39952354 DOI: 10.1016/j.jjcc.2025.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2024] [Revised: 01/26/2025] [Accepted: 02/07/2025] [Indexed: 02/17/2025]
Abstract
BACKGROUND In the era of high-sensitivity troponin assays, overdiagnosis of acute coronary syndrome (ACS) has become increasingly common, overriding underdiagnosis and carrying a burden of healthcare issues. This study aimed to assess the incidence, predictors, and sex differences in ACS overdiagnosis among patients presenting with chest pain (CP) to the emergency department (ED). METHODS Consecutive CP patients presenting at the ED were included. Patients with other causes of CP, non-suspicious for ACS, were excluded. Six-month ACS rate was assessed in discharged patients. In ACS hospitalized patients, clinical records were analyzed to evaluate true-ACS incidence. Patients inappropriately hospitalized for ACS (ACS-overdiagnosis, false-positives) were compared to correctly discharged (true-negatives) and actual ACS patients (true-positives and false-negatives). RESULTS From 7040 CP patients, a random sample of 1025 was included. ACS was initially diagnosed in 237 (23.1 %) patients who were hospitalized, while 788 (76.9 %) were discharged from the ED. ACS misdiagnosis occurred in 30 (2.9 %) patients: 8 (1 %) discharged patients experienced ACS at follow-up (false-negatives) while 22 (9.3 %) hospitalized for ACS were considered not to have ACS (ACS-overdiagnosis). True incident ACS at 6 months was 223 (21.8 %). Independent predictors of ACS overdiagnosis were electrocardiographic alterations, troponin T > 99° percentile, and male sex, while women were older with lower pre-test likelihood of ACS according to ED physicians, with a higher rate of early discharge but similar outcomes. CONCLUSIONS ACS overdiagnosis is more frequent than underdiagnosis, carrying potential issues for the healthcare system. Patients with ACS overdiagnosis were more commonly men with elevated high-sensitivity troponin, often indistinguishable from true-ACS patients according to standard care.
Collapse
Affiliation(s)
- Giorgio Fiore
- Unit of Cardiovascular Imaging, IRCCS Ospedale San Raffaele, Milan, Italy.
| | - Giuseppe Pinto
- IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Michele Oppizzi
- Unit of Cardiovascular Imaging, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Massimo Slavich
- Clinical Cardiology, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Federico Furlan
- Emergency Department, IRCCS San Raffaele Hospital, Milan, Italy
| | | | - Alberto Margonato
- Clinical Cardiology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | | |
Collapse
|
61
|
Yin YJ, Wang XW, Lu WQ, Chen ZY, Fu JY, Ren KF, Ji J. Adhesive polyelectrolyte coating on PLGA particles prolongs drug retention to vessel lesion. J Control Release 2025; 378:949-960. [PMID: 39733912 DOI: 10.1016/j.jconrel.2024.12.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2024] [Revised: 12/19/2024] [Accepted: 12/25/2024] [Indexed: 12/31/2024]
Abstract
Restenosis, the re-narrowing of blood vessels after drug-coated balloons (DCBs), remains a major clinical issue. While rapamycin is the current clinical option for preventing restenosis due to its effectiveness and low toxicity, its delivery is limited by poor tissue absorption and rapid clearance, leading to suboptimal drug retention. Here, we developed the adhesive-polyelectrolyte-coated poly(lactic-co-glycolic acid) (PLGA) particles using in-situ UV-triggered polymerization, encapsulating rapamycin. This system combines PLGA's sustained release with a robust adhesive coating that enhances vascular wall binding, by hydrogen bonding and covalent bonding. Rapamycin retention improved by 835 % in vitro (1 week) and 525 % in vivo (4 weeks) compared to uncoated particles. This approach offers a promising strategy to enhance rapamycin delivery, improving the safety and efficacy of DCBs in treating vessel obstruction.
Collapse
Affiliation(s)
- Yi-Jing Yin
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China
| | - Xing-Wang Wang
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China
| | - Wei-Qi Lu
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China
| | - Zhao-Yang Chen
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China; Center for Healthcare Materials, Shaoxing Institute, Zhejiang University, Shaoxing 312099, China
| | - Jia-Yin Fu
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China
| | - Ke-Feng Ren
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China; Center for Healthcare Materials, Shaoxing Institute, Zhejiang University, Shaoxing 312099, China; Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
| | - Jian Ji
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China; State Key Laboratory of Transvascular Implantation Devices, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310009, China.
| |
Collapse
|
62
|
Shaffer VA, Wegier P, Valentine KD, Duan S, Canfield SM, Belden JL, Steege LM, Popescu M, Koopman RJ. The Impact of an Enhanced Data Visualization Tool for Hypertension in the Electronic Health Record on Physician Judgments About Hypertension Control. J Gen Intern Med 2025:10.1007/s11606-025-09381-1. [PMID: 39920429 DOI: 10.1007/s11606-025-09381-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2024] [Accepted: 01/08/2025] [Indexed: 02/09/2025]
Abstract
PURPOSE Uncontrolled hypertension is a significant US health problem, despite existing effective treatments. This study assessed the impact of variations in patterns of blood pressure data on physician perceptions of hypertension control using different forms of data visualization. METHOD Physicians (N = 57) reviewed eight brief vignettes describing a fictitious patient; each vignette included a graph of the patient's blood pressure data. We examined how variations in mean systolic blood pressure (SBP), blood pressure standard deviation (SD), and form of visualization (e.g., line graph with raw values or smoothed values only) affected judgments about hypertension control and need for medication change. RESULTS Smoothing successfully reduced visual noise for the physicians. For controlled hypertension, physician judgments were more consistent with clinical guidelines when using the smoothed graph compared with the raw data graph. Judgments about hypertension control with the smoothed graph were similar to judgments made using the raw data graph for cases of uncontrolled hypertension. CONCLUSION Data visualization can direct physicians to attend to more clinically meaningful information, thereby improving their judgments of hypertension control.
Collapse
Affiliation(s)
| | - Pete Wegier
- Humber River Health & University of Toronto, Toronto, Canada
| | | | - Sean Duan
- University of Missouri, Columbia, MO, USA
| | | | | | | | | | | |
Collapse
|
63
|
Weiss L, O'Doherty A, Uhrig W, Szklanna PB, Hong-Minh M, Wynne K, Blanco A, Zivny J, Lima Passos V, Kevane B, Murphy S, Ní Áinle F, O'Donnell M, Maguire PB. Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease. J Thromb Haemost 2025; 23:531-545. [PMID: 39413927 DOI: 10.1016/j.jtha.2024.09.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 09/04/2024] [Accepted: 09/23/2024] [Indexed: 10/18/2024]
Abstract
BACKGROUND Despite secondary prevention with aspirin, patients with stable cardiovascular disease (CVD) remain at elevated long-term risk of major adverse cardiovascular events. The Cardiovascular Outcomes in People Using Anticoagulant Strategies (COMPASS) double-blind, randomized clinical trial demonstrated that aspirin plus low-dose rivaroxaban (COMPASS regime) significantly decreased the incidence of major adverse cardiovascular events by 24% compared with aspirin alone. However, the mechanisms underlying these potential synergistic/nonantithrombotic effects remain elusive. Extracellular vesicles (EVs) are crucial messengers regulating a myriad of biological/pathological processes and are highly implicated in CVD. OBJECTIVES We hypothesized that circulating EV profiles reflect the cardioprotective properties of the COMPASS regime. METHODS A cohort of stable CVD patients (N = 40) who participated in the COMPASS trial and were previously randomized to receive aspirin were prospectively recruited and assigned a revised regimen of open-label aspirin plus rivaroxaban. Blood samples were obtained at baseline (aspirin only) and 6-month follow-up. Plasma EV concentration, size, and origin were analyzed by nanoparticle tracking analysis and flow cytometry. EVs were enriched by ultracentrifugation for proteomic analysis. RESULTS The COMPASS regime fundamentally altered small (<200 nm) and large (200-1000 nm) EV concentration and size compared with aspirin alone. Crucially, levels of platelet-derived and myeloperoxidase-positive EVs became significantly decreased at follow-up. Comparative proteomic characterization further revealed a significant decrease in highly proinflammatory protein expression at follow-up. CONCLUSION The observed changes in EV subpopulations, together with the differential protein expression profiles, suggest amelioration of an underlying proinflammatory and prothrombotic state upon dual therapy, which may be of clinical relevance toward understanding the fundamental mechanism underlying the reported superior cardiovascular outcomes associated with this antithrombotic regimen.
Collapse
Affiliation(s)
- Luisa Weiss
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland; AI for Healthcare Hub, Institute for Discovery, O'Brien Centre for Science, University College Dublin, Dublin, Ireland. https://twitter.com/lweiss1311
| | - Aideen O'Doherty
- Health Research Board Clinical Research Facility Galway, School of Medicine, University of Galway, Galway, Ireland
| | - Wido Uhrig
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland
| | - Paulina B Szklanna
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
| | - Molly Hong-Minh
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
| | - Kieran Wynne
- Mass Spectrometry Core, Systems Biology Ireland, University College Dublin, Dublin, Ireland
| | - Alfonso Blanco
- Flow Cytometry Core, Conway Institute, University College Dublin, Dublin, Ireland
| | - Jan Zivny
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Valeria Lima Passos
- School of Pharmacy and Biomolecular Science, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Barry Kevane
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland
| | - Seán Murphy
- School of Medicine, University College Dublin, Dublin, Ireland; Department for Stroke Medicine, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Fionnuala Ní Áinle
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland; Department of Haematology, Rotunda Hospital, Dublin, Ireland. https://twitter.com/ConwaySPHERE
| | - Martin O'Donnell
- Health Research Board Clinical Research Facility Galway, School of Medicine, University of Galway, Galway, Ireland.
| | - Patricia B Maguire
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland; AI for Healthcare Hub, Institute for Discovery, O'Brien Centre for Science, University College Dublin, Dublin, Ireland.
| |
Collapse
|
64
|
Duong MH, Gnjidic D, McLachlan AJ, Winardi K, Bennett AA, Blyth F, Le Couteur D, Hilmer SN. Prevalence of heart failure pharmacotherapy utilisation, frailty and adverse drug events among hospitalised adults older than 75 years: a multicentre cross-sectional study. Intern Med J 2025; 55:249-259. [PMID: 39698760 DOI: 10.1111/imj.16612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2024] [Accepted: 11/26/2024] [Indexed: 12/20/2024]
Abstract
BACKGROUND Optimal heart failure (HF) pharmacotherapy (guideline-directed medical therapy and diuretics) in older people with frailty is uncertain due to limited evidence. AIMS To evaluate utilisation of HF pharmacotherapy and prevalence of polypharmacy, adverse drug events (ADEs), falls, delirium, renal impairment and duration of hospitalisation in older inpatients, according to frailty. METHODS A retrospective cross-sectional study of the TO HOME cohort of 2000 inpatients ≥75 years admitted for ≥48 h to rehabilitation, geriatric or general medicine from 1 July 2016 to 30 June 2017 across six hospitals in Sydney, Australia. Data were collected from electronic medical records. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification identified HF diagnosis, ADEs and frailty using hospital frailty risk score. Outcomes included utilisation of HF pharmacotherapy; polypharmacy; ADEs, falls, delirium, renal and impairment; and duration of hospitalisation. RESULTS Among 439 (22.0% of TO HOME cohort) patients with undifferentiated HF, 284 (69.5%) had intermediate or high risk of frailty, and 412 (94%) took ≥1 HF pharmacotherapy, with 357 (81.3%) patients on loop diuretics. Patients with high frailty risk frequently continued beta-blockers (70%) and discontinued renin-angiotensin system inhibitors (57%). Most patients experienced polypharmacy (n = 426, 97.0%). Renal impairment prevalence was 67%-76% across frailty groups. Increasing frailty risk (low, intermediate and high) was associated with increasing prevalence of ADEs (31%, 56% and 84%), falls (12%, 25% and 46%) and delirium (8%, 27% and 49%) and longer hospitalisation. CONCLUSIONS Frailty, HF-pharmacotherapy changes in hospital and ADEs were common among older inpatients with HF. The association of adverse outcomes according to frailty needs further investigation. Poor documentation of HF phenotype may be a barrier to medication optimisation in older inpatients.
Collapse
Affiliation(s)
- Mai H Duong
- Laboratory of Ageing and Pharmacology, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Danijela Gnjidic
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Andrew J McLachlan
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Kevin Winardi
- Laboratory of Ageing and Pharmacology, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia
| | - Alexandra A Bennett
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- NSW Therapeutic Advisory Group, Sydney, New South Wales, Australia
| | - Fiona Blyth
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - David Le Couteur
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Sarah N Hilmer
- Laboratory of Ageing and Pharmacology, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- NSW Therapeutic Advisory Group, Sydney, New South Wales, Australia
| |
Collapse
|
65
|
Yang C, Zhang N, Gao T, Zhu Y, Gong C, Xu M, Feng C. Association between social determinants of health and premature atherosclerotic cardiovascular disease and sex differences in US adults: A cross-sectional study. Prev Med Rep 2025; 50:102967. [PMID: 39897737 PMCID: PMC11786895 DOI: 10.1016/j.pmedr.2025.102967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Revised: 01/06/2025] [Accepted: 01/07/2025] [Indexed: 02/04/2025] Open
Abstract
Background Premature atherosclerotic cardiovascular disease (ASCVD) is a major public health issue, leading to productivity losses and higher healthcare costs. This study examines the association between social determinants of health (SDoH) and premature ASCVD, with a focus on sex differences. Method Data on self-reported SDoH based on Healthy People 2030 criteria were obtained from U.S. National Health and Nutrition Examination Surveys (2003-2018). Weighted logistic regression models were used to examine the relationship between SDoH (including eight sub-items and the cumulative number of unfavorable SDoH) and premature ASCVD. Analyses were further stratified by sex. Result A total of 40,536 participants aged ≥18 years (19,548 men and 20,888 women) were included in the analysis. The overall prevalence of premature ASCVD was 1756 cases, with a weighted estimate of 7,625,240. Although women had a lower prevalence of premature ASCVD (3.2 % [n = 784] vs. 4.3 % [n = 972]), they exhibited a higher level of unfavorable SDoH compared to men. Logistic regression indicated a 21 % increase in risk for each additional unfavorable SDoH (AOR = 1.21; 95 % CI, 1.16-1.26), and the cumulative number of unfavorable SDoH were positively associated with the odds of developing premature ASCVD (P for trend <0.01). Notably, the impact of unfavorable SDoH was greater in women, revealing significant sex disparities in susceptibility to premature ASCVD. Conclusion This study demonstrates that unfavorable SDoH significantly increase the risk of developing premature ASCVD. Furthermore, the cumulative effect of unfavorable SDoH pose a higher risk for women.
Collapse
Affiliation(s)
- Chun Yang
- Beijing Anzhen hospital, Capital Medical University, Beijing 100029, China
| | - Na Zhang
- Beijing Friendship Hospital, Capital Medical University, Beijing 100053, China
| | - Tiankuo Gao
- Beijing Anzhen hospital, Capital Medical University, Beijing 100029, China
| | - Yingxin Zhu
- Beijing Anzhen hospital, Capital Medical University, Beijing 100029, China
| | - Chen Gong
- Beijing Anzhen hospital, Capital Medical University, Beijing 100029, China
| | - Mingyue Xu
- Beijing Friendship Hospital, Capital Medical University, Beijing 100053, China
| | - Cuicui Feng
- Beijing Anzhen hospital, Capital Medical University, Beijing 100029, China
| |
Collapse
|
66
|
Alfadda AA, Youssef AM, Al-Sofiani ME, Amin HS, AlOtaibi O, Mohamed N, Algohani HA, Isnani A, Rafiullah M. Medication Adherence and Treatment Satisfaction With Lipid-Lowering Drugs Among Patients With Diabetes and Dyslipidemia. Ann Pharmacother 2025; 59:105-116. [PMID: 39054790 DOI: 10.1177/10600280241262513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2024] Open
Abstract
BACKGROUND Poor adherence to lipid-lowering drugs in diabetic patients with dyslipidemia increases has been linked with an increased cardiovascular risk. A better understanding of the determinants of adherence to lipid-lowering drugs and treatment satisfaction among people with diabetes and dyslipidemia is crucial. OBJECTIVE We aimed to assess the prevalence of adherence to lipid-lowering drugs, identify its determinant factors, and evaluate treatment satisfaction among users of lipid-lowering drugs who have diabetes and dyslipidemia. METHODS We surveyed 398 adult patients with diabetes and dyslipidemia, using a validated medication adherence survey (Adherence to Refills and Medications Scale) and a validated treatment satisfaction survey (Treatment Satisfaction Questionnaire for Medication, TSQM). Sociodemographic and medical history data were collected through questionnaires. RESULTS The prevalence of poor medication adherence was 36%. Factors associated with poor adherence included adverse reactions to medications, lack of medication availability, and lack of family support. Adherent patients reported lower low-density lipoprotein-cholesterol (LDL-C) and total cholesterol levels, higher treatment satisfaction, and a higher prevalence of cardiovascular disease and comorbidities. Having a family history of dyslipidemia was negatively associated with adherence, while the number of comorbidities positively influenced it. The scores of TSQM components such as effectiveness, global satisfaction, and convenience were significantly higher in people who were adherent or achieved the LDL-C target. CONCLUSION AND RELEVANCE Our findings highlight the need for interventions targeting several factors impacting adherence to lipid-lowering drugs in patients with diabetes and dyslipidemia. Managing adverse effects, leveraging family support, and ensuring medication access represent crucial aspects of improving adherence and potentially mitigating cardiovascular risks in this high-risk population.
Collapse
Affiliation(s)
- Assim A Alfadda
- Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Amira M Youssef
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Mohammed E Al-Sofiani
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Division of Endocrinology, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Hussein Saad Amin
- Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Obeed AlOtaibi
- University Diabetes Center, King Khalid University Hospital, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Nourhan Mohamed
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Hossam Ayed Algohani
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Arthur Isnani
- Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Mohamed Rafiullah
- Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
67
|
Liao Y, Li L, Li J, Zhao F, Zhang C. Uric Acid to Albumin Ratio: A Predictive Marker for Acute Kidney Injury in Isolated Tricuspid Valve Surgery. Rev Cardiovasc Med 2025; 26:26391. [PMID: 40026514 PMCID: PMC11868903 DOI: 10.31083/rcm26391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2024] [Revised: 11/12/2024] [Accepted: 11/21/2024] [Indexed: 03/05/2025] Open
Abstract
Background The plasma uric acid/albumin ratio (UAR) has emerged as a novel inflammatory biomarker for predicting the development of acute kidney injury (AKI) following percutaneous coronary intervention. However, the potential of the UAR to serve as a predictive marker for AKI in patients undergoing isolated tricuspid valve (TV) surgery remains unknown. This study aimed to explore the association between the UAR and AKI and to assess whether the UAR can predict AKI in these patients. Methods We conducted a retrospective analysis of patients who underwent isolated TV surgery between January 2018 and June 2019. The patients were divided into three groups based on the tertiles of the UAR. We utilized multivariate logistic regression and restricted cubic spline analysis to examine the association between the UAR and AKI. Additionally, we used the receiver operating characteristic (ROC) curve analysis to assess the predictive accuracy of the UAR for AKI. Results A total of 224 patients were enrolled in this study, of whom 41 developed AKI. The incidence of AKI across the three UAR tertiles was 3.8%, 22.2%, and 29.7%, with a significant difference between the group (p < 0.001). In the multivariate analysis, UAR ≥8.5 was associated with a 7-fold increased risk of AKI (odds ratio (OR): 7.73, 95% confidence interval (CI): 1.61-37.14), while a UAR ≥10.8 was a linked to a 9-fold increased risk (OR: 9.34, 95% CI: 1.96-44.60). The restricted cubic spline model showed a linear association between the UAR and AKI development. The area under the curve (AUC) value for the UAR was 0.713 (95% CI: 0.633-0.793; p < 0.001) with a cutoff value of 8.89. Conclusions An increased UAR was significantly associated with a higher risk of AKI in patients undergoing isolated TV surgery; however, while the UAR could serve as a marker to predict AKI, it was not superior to uric acid alone.
Collapse
Affiliation(s)
- Yaoji Liao
- Department of Cardiac Surgery Intensive Care Unit, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China
| | - Liuyuan Li
- Department of Cardiac Surgery Intensive Care Unit, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China
| | - Jie Li
- Department of Cardiac Surgery Intensive Care Unit, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China
| | - Feifei Zhao
- Department of Cardiac Surgery Intensive Care Unit, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China
| | - Chongjian Zhang
- Department of Cardiac Surgery Intensive Care Unit, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China
| |
Collapse
|
68
|
di Biase L, Bonura A, Pecoraro PM, Di Lazzaro V. Real-world safety profile of direct oral anticoagulants (DOACs): Disproportionality analysis of major bleeding events. J Stroke Cerebrovasc Dis 2025; 34:108173. [PMID: 39643068 DOI: 10.1016/j.jstrokecerebrovasdis.2024.108173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2024] [Revised: 11/24/2024] [Accepted: 12/03/2024] [Indexed: 12/09/2024] Open
Abstract
BACKGROUND Direct Oral Anticoagulants (DOACs) have revolutionized the management of thrombotic conditions, providing more predictable and manageable anticoagulation compared to traditional vitamin K antagonists. Despite their success, major bleeding events remain a significant concern. This study aims to assess and compare the haemorrhagic risks associated with various DOACs using data from the FDA's Adverse Event Reporting System (FAERS). METHODS A retrospective disproportionality analysis of the FAERS database was conducted, covering the period from January 1, 2015, to December 31, 2023. The study focused on adverse bleeding events reported for DOACs. The Proportional Reporting Ratio (PRR) was calculated for each DOAC to identify disproportionate reporting of haemorrhagic events. Major haemorrhagic events were classified as those leading to hospitalization. The analysis also utilized the Medicare Part D dataset to estimate the usage of specific DOACs from 2015 to 2021. RESULTS A total of 353,188 haemorrhagic events were identified, with 17,236 (4.9%) attributed to DOACs. The PRR for major haemorrhagic events was highest for Edoxaban at 14.1 (95% CI 13.93-14.85), followed by Dabigatran at 4.0 (95% CI 3.81-4.20), Apixaban at 3.53 (95% CI 3.47-3.61), and Rivaroxaban at 2.11 (95% CI 2.05-2.18). Edoxaban also had the highest PRR for cerebral haemorrhages. Medicare data indicated that Apixaban was the most commonly used DOAC (58.3%), followed by Rivaroxaban (34.5%). CONCLUSIONS Edoxaban shows a significantly higher risk of major and cerebral haemorrhages compared to other DOACs, while Rivaroxaban demonstrates a lower overall risk of haemorrhage. These findings emphasize the need for careful consideration of bleeding risks in DOAC therapy. Continuous post-marketing surveillance is crucial for understanding the safety profiles of DOACs in real-world clinical settings, aiding clinicians and patients in making informed decisions about anticoagulant therapy.
Collapse
Affiliation(s)
- Lazzaro di Biase
- Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128, Roma, Italy; Brain Innovations Lab, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128, Rome, Italy.
| | - Adriano Bonura
- Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128, Roma, Italy; Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128, Roma, Italy
| | - Pasquale Maria Pecoraro
- Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128, Roma, Italy; Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128, Roma, Italy
| | - Vincenzo Di Lazzaro
- Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128, Roma, Italy; Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128, Roma, Italy
| |
Collapse
|
69
|
Axt J, To J. How Can Debiasing Research Aid Efforts to Reduce Discrimination? PERSONALITY AND SOCIAL PSYCHOLOGY REVIEW 2025; 29:81-105. [PMID: 38647090 PMCID: PMC11734358 DOI: 10.1177/10888683241244829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
PUBLIC ABSTRACT Scientists studying intergroup biases are often concerned with lessening discrimination (unequal treatment of one social group versus another), but many interventions for reducing such biased behavior have weak or limited evidence. In this review article, we argue one productive avenue for reducing discrimination comes from adapting interventions in a separate field-judgment and decision-making-that has historically studied "debiasing": the ways people can lessen the unwanted influence of irrelevant information on decision-making. While debiasing research shares several commonalities with research on reducing intergroup discrimination, many debiasing interventions have relied on methods that differ from those deployed in the intergroup bias literature. We review several instances where debiasing principles have been successfully applied toward reducing intergroup biases in behavior and introduce other debiasing techniques that may be well-suited for future efforts in lessening discrimination.
Collapse
Affiliation(s)
- Jordan Axt
- McGill University, Montreal, Quebec, Canada
| | - Jeffrey To
- McGill University, Montreal, Quebec, Canada
| |
Collapse
|
70
|
Johnson LCM, Josiah Willock R, Simmons S, Moyd S, Geiger D, Ghali JK, Quarells RC. COVID-19 Prevention and Mitigation Decision-Making Processes While Navigating Chronic Disease Care: Perspectives of Black Adults with Heart Failure and Diabetes. J Racial Ethn Health Disparities 2025; 12:181-190. [PMID: 38702490 PMCID: PMC11531604 DOI: 10.1007/s40615-023-01862-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 11/01/2023] [Accepted: 11/02/2023] [Indexed: 05/06/2024]
Abstract
BACKGROUND Heart failure and diabetes are comorbidities that disproportionately contribute to high morbidity and mortality among Blacks. Further compounding the racial and ethnic disparities in COVID-19 health outcomes, Blacks with cardiometabolic diseases are at high risk of experiencing serious complications or mortality from COVID-19. This study aimed to assess how Blacks with heart failure and diabetes navigated chronic care management during the COVID-19 pandemic. METHODS A mixed methods study including in-depth interviews and surveys with adults diagnosed with heart failure and diabetes (n = 17) was conducted in 2021-2022. Verbatim transcripts were analyzed using a thematic analysis approach. RESULTS Participants reported that while the pandemic initially caused delays in access to health services, shifts to telemedicine allowed for continued care despite preferences for in-person appointments. Various sources of information were used in different ways to make decisions on how to best reduce health risks due to COVID-19, but individuals and institutions affiliated with science and medicine, or who promoted information from these sources, were considered to be the most trusted sources of information among those who relied on outside guidance when making health-related decisions. Individuals' self-awareness of their own high-risk status and perceived control over their exposure levels to the virus informed what COVID-19 prevention and mitigation strategies people used. CONCLUSION Information backed by scientific data was an important health communication tool that alongside other factors, such as fear of mortality due to COVID-19, encouraged individuals to get vaccinated and adopt other COVID-19 prevention and mitigation behaviors.
Collapse
Affiliation(s)
- Leslie C M Johnson
- Department of Family and Preventive Medicine, Emory University School of Medicine, 1518 Clifton Rd, Atlanta, GA, USA
| | | | - Sierra Simmons
- Biology Department, Spelman College, 350 Spelman Lane SW, Atlanta, GA, USA
| | - Sarahna Moyd
- Gangarosa Department of Environmental Health, Rollins School of Public Health, 1518 Clifton Rd NE, Atlanta, GA, USA
| | - Demetrius Geiger
- Health Equity Programs Department, CHC: Creating Healthier Communities, 1199 North Fairfax Street, Alexandria, VA, USA
| | - Jalal K Ghali
- Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA, USA
| | | |
Collapse
|
71
|
Chen A, Zhang Y, Zhang J. Explainable machine learning and online calculators to predict heart failure mortality in intensive care units. ESC Heart Fail 2025; 12:353-368. [PMID: 39300773 PMCID: PMC11769656 DOI: 10.1002/ehf2.15062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 06/10/2024] [Accepted: 08/21/2024] [Indexed: 09/22/2024] Open
Abstract
AIMS This study aims to develop explainable machine learning models and clinical tools for predicting mortality in patients in the intensive care unit (ICU) with heart failure (HF). METHODS Patients diagnosed with HF who experienced their first ICU stay lasting between 24 h and 28 days were selected from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The primary outcome was all-cause mortality within 28 days. Data analysis was performed using Python and R, with feature selection conducted via least absolute shrinkage and selection operator (LASSO) regression. Fifteen models were evaluated, and the most effective model was rendered explainable through the Shapley additive explanations (SHAP) approach. A nomogram was developed based on logistic regression to facilitate interpretation. For external validation, the eICU database was utilized. RESULTS After selection, the study included 2343 records, with 1808 surviving and 535 deceased patients. The median age of the study population was 70.00, with ~3/5 males (60.31%). The median length of stay in the ICU was 6.00 days. The median age of the survival group was younger than the non-survival group (69.00 vs. 73.00), and non-survival patients spent longer time in the ICU. Seventy-five features were initially selected, including basic information, vital signs, laboratory tests, haemodynamics and oxygen status. LASSO regression determined the shrinkage parameter α = 0.020, and 44 features were chosen for model construction. The linear discriminant analysis (LDA) model showed the best performance, and the accuracy reached 0.8354 in the training cohort and 0.8563 in the testing cohort. It showed satisfying area under the curve (AUC), recall, precision, F1 score, Cohen's kappa score and Matthew's correlation coefficient. The concordance index (c-index) reached 0.7972 in the training cohort and 0.8125 in the testing cohort. In external validation, the LDA model achieved approximately 0.9 in accuracy, precision, recall and F1 score, with an AUC of 0.79. Univariable analysis was performed in the training cohort. Features that differed significantly between the survival and non-survival groups were subjected to multiple logistic regression. The nomogram built on multiple logistic regression included 14 features and demonstrated excellent performance. The AUC of the nomogram is 0.852 in the training cohort, 0.855 in the internal validation cohort and 0.770 in the external validation cohort. The calibration curve showed good consistency. CONCLUSIONS The study developed an LDA and a nomogram model for predicting mortality in HF patients in the ICU. The SHAP approach was employed to elucidate the LDA model, enhancing its utility for clinicians. These models were made accessible online for clinical application.
Collapse
Affiliation(s)
- An‐Tian Chen
- Department of CardiologyFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular DiseasesBeijingChina
- Heart Failure CenterFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular DiseasesBeijingChina
- Department of Computer Science, College of Natural SciencesThe University of Texas at AustinAustinTexasUSA
| | - Yuhui Zhang
- Heart Failure CenterFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular DiseasesBeijingChina
| | - Jian Zhang
- Heart Failure CenterFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular DiseasesBeijingChina
- Key Laboratory of Clinical Research for Cardiovascular MedicationsNational Health CommitteeBeijingChina
| |
Collapse
|
72
|
Mohammed M, Zainal H, Ong SC, Tangiisuran B, Aziz FA, Sidek NN, Sha'aban A, Ibrahim UI, Muhammad S, Looi I, Aziz ZA. Prognostic Models of Mortality Following First-Ever Acute Ischemic Stroke: A Population-Based Retrospective Cohort Study. Health Sci Rep 2025; 8:e70445. [PMID: 39957974 PMCID: PMC11825595 DOI: 10.1002/hsr2.70445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 01/20/2025] [Accepted: 01/27/2025] [Indexed: 02/18/2025] Open
Abstract
Background and Aims There is a lack of population-based studies focusing on guideline-based prognostic models for stroke. This study aimed to develop and validate a prognostic model that predicts mortality following a first-ever acute ischemic stroke. Methods The study included 899 adult patients ( ≥ 18 years) with confirmed diagnosis of first-ever acute ischemic stroke enrolled in the Malaysian National Stroke Registry (NSR) from January 2009 to December 2019. The primary outcome was mortality within 90 days post-stroke (266 events [29.6%]). The prognostic model was developed using logistic regression (75%, n = 674) and internally validated (25%, n = 225). Model performance was assessed using discrimination (area under the curve (AUC]) and calibration (Hosmer-Lemeshow test [HL]). Results The final model includes factors associated with increased risk of mortality, such as age (adjusted odds ratio, aOR 1.06 [95% confidence interval, CI 1.03, 1.10; p < 0.001]), National Institutes of Health Stroke Scale (NIHSS) score aOR 1.08 (95% CI 1.08, 1.13; p = 0.004), and diabetes aOR 2.29 (95% CI 1.20, 4.37; p = 0.012). The protective factors were antiplatelet within 48 h. aOR 0.40 (95% CI 0.19, 0.81; p = 0.01), dysphagia screening aOR 0.30 (95% CI 0.15, 0.61; p = 0.001), antiplatelets upon discharge aOR 0.17 (95% CI 0.08, 0.35; p < 0.001), lipid-lowering therapy aOR 0.37 (95% CI 0.17, 0.82; p = 0.01), stroke education aOR 0.02 (95% CI 0.01, 0.05; p < 0.001) and rehabilitation aOR 0.08 (95% CI 0.04, 0.16; p < 0.001). The model demonstrated excellent performance (discrimination [AUC = 0.94] and calibration [HL, X 2 p = 0.63]). Conclusion The study developed a validated prognostic model that excellently predicts mortality after a first-ever acute ischemic stroke with potential clinical utility in acute stroke care decision-making. The predictors could be valuable for creating risk calculators and aiding healthcare providers and patients in making well-informed clinical decisions during the stroke care process.
Collapse
Affiliation(s)
| | - Hadzliana Zainal
- School of Pharmaceutical SciencesUniversiti Sains MalaysiaPulau PinangMalaysia
| | - Siew Chin Ong
- School of Pharmaceutical SciencesUniversiti Sains MalaysiaPulau PinangMalaysia
| | | | | | - Norsima N. Sidek
- Clinical Research CenterHospital Sultanah Nur ZahirahTerengganuMalaysia
| | | | - Umar Idris Ibrahim
- Faculty of PharmacyUniversiti Sultan Zainal AbidinKuala TerengganuMalaysia
| | | | - Irene Looi
- Clinical Research CenterHospital Seberang JayaPulau PinangMalaysia
| | - Zariah A. Aziz
- Clinical Research CenterHospital Sultanah Nur ZahirahTerengganuMalaysia
| |
Collapse
|
73
|
Kizilkilic EK, Akan YN, Atbas B, Karagöz SH, Korkmazer B, Arslan S, Islak C, Kocer N, Kizilkilic O. Results of carotid stenting in patients with contralateral internal carotid artery occlusion: a retrospective single-center analysis and 22 years of experience. Neuroradiology 2025; 67:393-401. [PMID: 39708158 DOI: 10.1007/s00234-024-03524-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 12/07/2024] [Indexed: 12/23/2024]
Abstract
PURPOSE Patients with contralateral carotid artery occlusion (CCO) represent a subgroup of patients at risk for revascularization procedures. The choice of appropriate revascularization procedure (carotid endarterectomy (CEA) or carotid artery stenting (CAS)) in these patients is controversial. The aim of this study is to share the results of clinical and radiological follow-up after CAS in these patients and to contribute to the literature by evaluating the efficacy and safety of stenting. METHODS In our study, the clinical and radiological data of 145 patients with CCO and 145 age-gender-matched patients without CCO who underwent elective CAS in the interventional neuroradiology clinic between 2001 and 2023 were retrospectively analyzed. A comparison was made between short- and long-term outcomes between the two groups. RESULTS The overall technical success rate of CAS was 99.7% and the 30-day all-cause mortality rate was 1.4%. There was no statistically significant difference between the two groups in terms of early-term (intra-procedural thromboembolic events, post-procedural symptomatic hyperperfusion, intraparenchymal hemorrhage, major and minor ischemic stroke, early-term mortality rate) and long-term (intimal hyperplasia, residual stenosis, major and minor ischemic stroke and long-term all-cause mortality rate) (p > 0.05). CONCLUSION In our experience, it was concluded that CAS performed by an experienced interventional neuroradiology team in patients with CCO does not pose an additional risk. Since CCO poses a risk for CAE, CAS may be a more acceptable treatment modality in these patients due to less perioperative risk. However, further research is required to support our findings.
Collapse
Affiliation(s)
- Esra Kochan Kizilkilic
- Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University- Cerrahpasa, Istanbul, Türkiye
| | - Yeşim Namdar Akan
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Baran Atbas
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Seyfullah Halit Karagöz
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Bora Korkmazer
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Serdar Arslan
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Civan Islak
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Naci Kocer
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye
| | - Osman Kizilkilic
- Department of Neuroradiology, Cerrahpaşa Faculty of Medicine, Istanbul University-, Cerrahpaşa, Istanbul, Türkiye.
| |
Collapse
|
74
|
Ungvari A, Gulej R, Patai R, Papp Z, Toth A, Szabó AÁ, Podesser BK, Sótonyi P, Benyó Z, Yabluchanskiy A, Tarantini S, Maier AB, Csiszar A, Ungvari Z. Sex-specific mechanisms in vascular aging: exploring cellular and molecular pathways in the pathogenesis of age-related cardiovascular and cerebrovascular diseases. GeroScience 2025; 47:301-337. [PMID: 39754010 PMCID: PMC11872871 DOI: 10.1007/s11357-024-01489-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2024] [Accepted: 12/17/2024] [Indexed: 03/04/2025] Open
Abstract
Aging remains the foremost risk factor for cardiovascular and cerebrovascular diseases, surpassing traditional factors in epidemiological significance. This review elucidates the cellular and molecular mechanisms underlying vascular aging, with an emphasis on sex differences that influence disease progression and clinical outcomes in older adults. We discuss the convergence of aging processes at the macro- and microvascular levels and their contributions to the pathogenesis of vascular diseases. Critical analysis of both preclinical and clinical studies reveals significant sex-specific variations in these mechanisms, which could be pivotal in understanding the disparity in disease morbidity and mortality between sexes. The review highlights key molecular pathways, including oxidative stress, inflammation, and autophagy, and their differential roles in the vascular aging of males and females. We argue that recognizing these sex-specific differences is crucial for developing targeted therapeutic strategies aimed at preventing and managing age-related vascular pathologies. The implications for personalized medicine and potential areas for future research are also explored, emphasizing the need for a nuanced approach to the study and treatment of vascular aging.
Collapse
Affiliation(s)
- Anna Ungvari
- Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary.
| | - Rafal Gulej
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Roland Patai
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Zoltan Papp
- Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
- Research Centre for Molecular Medicine, University of Debrecen, Debrecen, 4032, Hungary
| | - Attila Toth
- Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
- Research Centre for Molecular Medicine, University of Debrecen, Debrecen, 4032, Hungary
| | - Attila Á Szabó
- Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
- Research Centre for Molecular Medicine, University of Debrecen, Debrecen, 4032, Hungary
| | - Bruno K Podesser
- Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria
| | - Péter Sótonyi
- Department of Vascular and Endovascular Surgery, Heart and Vascular Centre, Semmelweis University, 1122, Budapest, Hungary
| | - Zoltán Benyó
- Institute of Translational Medicine, Semmelweis University, 1094, Budapest, Hungary
- Cerebrovascular and Neurocognitive Disorders Research Group, HUN-REN , Semmelweis University, 1094, Budapest, Hungary
| | - Andriy Yabluchanskiy
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Doctoral College/Institute of Preventive Medicine and Public Health, International Training Program in Geroscience, Semmelweis University, Budapest, Hungary
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA
- Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Department of Health and Exercise Science, University of Oklahoma, Norman, OK, USA
- Reynolds Section of Geriatrics and Palliative Medicine, Department of Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK, USA
| | - Stefano Tarantini
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Doctoral College/Institute of Preventive Medicine and Public Health, International Training Program in Geroscience, Semmelweis University, Budapest, Hungary
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA
- Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Andrea B Maier
- Department of Medicine and Aged Care, @AgeMelbourne, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
- Department of Human Movement Sciences, @AgeAmsterdam, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, the Netherlands
- Centre for Healthy Longevity, @AgeSingapore, National University Health System, Singapore, Singapore
- @AgeSingapore, Healthy Longevity Program, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore
| | - Anna Csiszar
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA
- Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Zoltan Ungvari
- Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Doctoral College/Institute of Preventive Medicine and Public Health, International Training Program in Geroscience, Semmelweis University, Budapest, Hungary
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA
- Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| |
Collapse
|
75
|
Langenbach IL, Hadzic I, Zeleznik R, Langenbach MC, Maintz D, Mayrhofer T, Lu MT, Aerts HJWL, Foldyna B, Weintraub E. Association of Epicardial Adipose Tissue Changes on Serial Chest CT Scans with Mortality: Insights from the National Lung Screening Trial. Radiology 2025; 314:e240473. [PMID: 39964263 PMCID: PMC11868846 DOI: 10.1148/radiol.240473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 12/01/2024] [Accepted: 12/11/2024] [Indexed: 03/03/2025]
Abstract
Background Individuals eligible for lung cancer screening with low-dose CT face a higher cardiovascular mortality risk. Purpose To investigate the association between changes in epicardial adipose tissue (EAT) at the 2-year interval and mortality in individuals undergoing serial low-dose CT lung cancer screening. Materials and Methods This secondary analysis of the National Lung Screening Trial obtained EAT volume and density from serial low-dose CT scans using a validated automated deep learning algorithm. EAT volume and density changes over 2 years were categorized into typical (decrease of 7% to increase of 11% and decrease of 3% to increase of 2%, respectively) and atypical (increase or decrease beyond typical) changes, which were associated with all-cause, cardiovascular, and lung cancer mortality. Uni- and multivariable Cox proportional hazard regression models-adjusted for baseline EAT values, age, sex, race, ethnicity, smoking, pack-years, heart disease or myocardial infarction, stroke, hypertension, diabetes, education status, body mass index, and coronary artery calcium-were performed. Results Among 20 661 participants (mean age, 61.4 years ± 5.0 [SD]; 12 237 male [59.2%]), 3483 (16.9%) died over a median follow-up of 10.4 years (IQR, 9.9-10.8 years) (cardiovascular related: 816 [23.4%]; lung cancer related: 705 [20.2%]). Mean EAT volume increased (2.5 cm3/m2 ± 11.0) and density decreased (decrease of 0.5 HU ± 3.0) over 2 years. Atypical changes in EAT volume were independent predictors of all-cause mortality (atypical increase: hazard ratio [HR], 1.15 [95% CI: 1.06, 1.25] [P < .001]; atypical decrease: HR, 1.34 [95% CI: 1.23, 1.46] [P < .001]). An atypical decrease in EAT volume was associated with cardiovascular mortality (HR, 1.27 [95% CI: 1.06, 1.51]; P = .009). EAT density increase was associated with all-cause, cardiovascular, and lung cancer mortality (HR, 1.29 [95% CI: 1.18, 1.40] [P < .001]; HR, 1.29 [95% CI: 1.08, 1.54] [P = .005]; HR, 1.30 [95% CI: 1.07, 1.57] [P = .007], respectively). Conclusion EAT volume increase and decrease and EAT density increase beyond typical on subsequent chest CT scans were associated with all-cause mortality in participants screened for lung cancer. EAT volume decrease and EAT density increase were associated with elevated risk of cardiovascular mortality after adjustment for baseline EAT values. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Fuss in this issue.
Collapse
Affiliation(s)
- Isabel L. Langenbach
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Ibrahim Hadzic
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Roman Zeleznik
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Marcel C. Langenbach
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - David Maintz
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Thomas Mayrhofer
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Michael T. Lu
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Hugo J. W. L. Aerts
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Borek Foldyna
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| | - Elizabeth Weintraub
- From the Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, 165 Cambridge St, Ste 400, Boston, MA
02114 (I.L.L., M.C.L., T.M., M.T.L., B.F.); Institute for Diagnostic and
Interventional Radiology, University Hospital Cologne, Cologne, Germany (I.L.L.,
M.C.L., D.M.); Artificial Intelligence in Medicine Program, Mass General
Brigham, Harvard Medical School, Boston, Mass (I.H., R.Z., H.J.W.L.A.);
Department of Radiation Oncology, Brigham and Women’s Hospital,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (I.H., R.Z.,
H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CARIM & GROW,
Maastricht University, Maastricht, the Netherlands (I.H., H.J.W.L.A.); and
School of Business Studies, Stralsund University of Applied Sciences, Stralsund,
Germany (T.M.)
| |
Collapse
|
76
|
Tanaka K, Yamaguchi J, Yoshikawa M, Shibahashi E, Otsuki H, Kawamoto T, Koyanagi C, Inagaki Y, Kogure T, Yamamoto M, Saji M, Asami M, Nakashima M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Kubo S, Nakajima Y, Naganuma T, Bota H, Ohno Y, Yamawaki M, Ueno H, Mizutani K, Otsuka T, Hayashida K. Effect of Renal Impairment on Clinical Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair. JACC. ASIA 2025; 5:273-282. [PMID: 39967218 PMCID: PMC11840231 DOI: 10.1016/j.jacasi.2024.10.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Revised: 10/16/2024] [Accepted: 10/28/2024] [Indexed: 02/20/2025]
Abstract
BACKGROUND Renal impairment is associated with poor clinical outcomes in patients with cardiovascular diseases. Some studies have revealed the impact of renal impairment on the clinical outcomes of patients who underwent mitral valve transcatheter edge-to-edge repair (M-TEER). However, limited data are available regarding the impact of baseline renal impairment after M-TEER in Asian-Pacific patients with heart failure and severe mitral regurgitation. OBJECTIVES This study sought to examine the effect of renal impairment on clinical outcomes after M-TEER using a large-scale nationwide registry in Japan. METHODS A total of 2,150 patients enrolled in the OCEAN-Mitral (Optimized Catheter Valvular Intervention) registry were divided into 3 groups according to the estimated glomerular filtration rate (eGFR) before M-TEER: normal eGFR (≥60 mL/min/1.73 m2) (n = 291), renal impairment (<60 mL/min/1.73 m2) (n = 1,746), and dialysis (n = 113). The impact of renal impairment and dialysis on major adverse cardiovascular events (MACE) (a composite of all-cause death and hospitalization for heart failure) was examined. RESULTS Kaplan-Meier analysis revealed that the renal impairment and dialysis groups had a significantly higher incidence of MACE (survival rates at 2 years: normal eGFR, 74.2% [95% CI: 66.9%-80.1%] vs renal impairment, 63.9% [95% CI: 61.0%-66.6%] vs dialysis, 50.9% [95% CI: 38.2%-62.2%]; P < 0.001). Multivariate Cox regression analysis identified dialysis as the strongest independent predictor of MACE (HR: 1.95; 95% CI: 1.33-2.85; P < 0.001). CONCLUSIONS Renal impairment was associated with an increased incidence of major adverse events, and dialysis was the strongest independent predictor of poor clinical outcomes after M-TEER in Asian-Pacific patients.
Collapse
Affiliation(s)
- Kazuki Tanaka
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Junichi Yamaguchi
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
| | | | - Eiji Shibahashi
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Hisao Otsuki
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Takanori Kawamoto
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Chihiro Koyanagi
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Yusuke Inagaki
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Tomohito Kogure
- Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan
| | - Masanori Yamamoto
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan; Department of Cardiology, Nagoya Heart Center, Nagoya, Japan; Department of Cardiology, Gifu Heart Center, Gifu, Japan
| | - Mike Saji
- Department of Cardiology, Sakakibara Heart Institute, Okayama, Japan; Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan
| | - Masahiko Asami
- Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan
| | | | - Yusuke Enta
- Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan
| | - Shinichi Shirai
- Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan
| | - Masaki Izumo
- Division of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan
| | - Shingo Mizuno
- Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan
| | - Yusuke Watanabe
- Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan
| | - Makoto Amaki
- Department of Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Kazuhisa Kodama
- Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan
| | - Shunsuke Kubo
- Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
| | - Yoshifumi Nakajima
- Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
| | - Toru Naganuma
- Department of Cardiology, New Tokyo Hospital, Chiba, Japan
| | - Hiroki Bota
- Department of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan
| | - Yohei Ohno
- Department of Cardiology, Tokai University School of Medicine, Isehara, Japan
| | | | - Hiroshi Ueno
- Second Department of Internal Medicine, Toyama University Hospital, Toyama, Japan
| | - Kazuki Mizutani
- Division of Cardiology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan
| | - Toshiaki Otsuka
- Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan
| | - Kentaro Hayashida
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
77
|
Yogeeta F, Devi M, Rauf SA, Tooba F, Sumar KA, Haque MA. Pulmonary Embolism: Highlighting Iron Deficiency Anemia as a Contributing Factor in the Development of Pulmonary Embolism-A Case Report. Clin Case Rep 2025; 13:e70158. [PMID: 39872706 PMCID: PMC11769967 DOI: 10.1002/ccr3.70158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2024] [Revised: 12/17/2024] [Accepted: 01/08/2025] [Indexed: 01/30/2025] Open
Abstract
This case emphasizes iron deficiency anemia (IDA) as a potential risk factor for pulmonary embolism (PE), especially in patients with type 2 diabetes. Early recognition and management of PE and IDA are crucial. Further research is needed to clarify the mechanisms linking IDA to thrombosis and improve prevention strategies.
Collapse
Affiliation(s)
- Fnu Yogeeta
- Liaquat National Medical CollegeKarachiPakistan
| | - Muskan Devi
- Liaquat National Medical CollegeKarachiPakistan
| | | | - Fnu Tooba
- Liaquat National Medical CollegeKarachiPakistan
| | | | - Md Ariful Haque
- Department of Public HealthAtish Dipankar University of Science and TechnologyDhakaBangladesh
- Voice of Doctors Research SchoolDhakaBangladesh
- Department of Orthopaedic SurgeryYan'an Hospital Affiliated to Kunming Medical UniversityKunmingYunnanChina
| |
Collapse
|
78
|
Ahmadzadeh AM, Pourbagher-Shahri AM, Forouzanfar F. Neuroprotective effects of phytochemicals through autophagy modulation in ischemic stroke. Inflammopharmacology 2025; 33:729-757. [PMID: 39884996 DOI: 10.1007/s10787-024-01606-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Accepted: 11/14/2024] [Indexed: 02/01/2025]
Abstract
Stroke is a serious life-threatening medical condition. Understanding the underlying molecular mechanisms of this condition is crucial to identifying novel therapeutic targets that can improve patient outcomes. Autophagy is an essential mechanism for the destruction of damaged intracellular components that maintains homeostasis in physiological or pathological conditions. This process is involved in the pathophysiology of stroke. Phytochemicals are bioactive naturally occurring compounds present in plants. This paper reviews the neuroprotective roles of phytochemicals in ischemic stroke through autophagy modulation. It summarizes the interactions of various phytochemicals with key molecular targets of the autophagy pathway in ischemic stroke, including PI3K/Akt/mTOR, Beclin-1, and AMPK. Due to the ability of various phytochemicals to alter autophagic flux, they may provide promising opportunities in the development of new treatments and the improvement of stroke management.
Collapse
Affiliation(s)
- Amir Mahmoud Ahmadzadeh
- Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Radiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | | | - Fatemeh Forouzanfar
- Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
79
|
Fisher L, Ben-Shabat N, Gendelman O, Sharif K, Ehrenberg S, Shani U, Patt YS, Karra N, Watad A, Amital H, Cohen A, Dudkiewicz I. Risk of atherosclerosis-related diseases in polymyositis and dermatomyositis patients: A large-scale population-based study. Atherosclerosis 2025; 401:119100. [PMID: 39818113 DOI: 10.1016/j.atherosclerosis.2024.119100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 12/18/2024] [Accepted: 12/18/2024] [Indexed: 01/18/2025]
Abstract
BACKGROUND AND AIMS Several systemic autoimmune diseases predispose to the enhancement of Atherosclerotic Cardiovascular Disease (ASCVD). These findings underline the role of inflammation in atherogenesis. Dermatomyositis (DM) and polymyositis (PM) are polygenic autoimmune disorders involving mainly skeletal muscles. The association between PM/DM and ASCVD has not been well addressed and explored. We aimed to investigate the association between PM/DM and ASCVD events, we examined the incidence, mortality, and interaction of disease-modifying agents, autoantibodies, and traditional cardiovascular disease (CVD) risk factors in a large population-based sample. METHODS We conducted a retrospective cohort study using the electronic database of Clalit Health Services (CHS), the largest health organization in Israel. All DM and PM patients diagnosed between 2000 and 2016 were included and matched with healthy controls by age and sex in a 1:5 ratio. Follow-up continued until the first diagnosis of ASCVD or death. The incidence of ASCVD was compared between the groups using univariate and multivariate models adjusting for baseline cardiovascular risk factors. RESULTS The study population included 1899 PM/DM patients and 7676 controls. The mean age at the index date was 32.5 years (SD ± 19 years), and the female proportion was 60.3 %, similar for both groups. Traditional cardiovascular risk factors were similar in both groups. The Median follow-up time was 8.4 years (3.6-12.8) in the PM/DM group compared to 8.6 (3.7-12.9) in the control group. 47 (3.0 %) PM/DM patients were diagnosed with ischemic heart disease (IHD) compared to 1.8 % (140) in the controls, yielding a multivariate HR (95%CI) of 1.61 (1.15-2.25). Multivariate HR for cerebrovascular accident (CVA) in the PM/DM group was (95%CI) 2.45 (1.63-3.70). Multivariate HR for ASCVD. (95%CI) was 1.75 (1.35-2.27) in the PM/DM group. APLA-associated antibodies presence was more associated with ASCVD among PM/DM groups than non-ASCVD PM and DM patients (OR 2.33, 95 % CI 1.41-3.86, p < 0.001). CONCLUSIONS Our study demonstrates that PM and DM are associated with an increased risk of IHD and CVA. Furthermore, PM and DM patients positive for APLA-associated antibodies exhibited excessive rates of ASCVD. These findings support the increased need for awareness and surveillance of cardiological, neuronal, and vascular outcomes in patients suffering from PM/DM.
Collapse
Affiliation(s)
- Lior Fisher
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
| | - Niv Ben-Shabat
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Omer Gendelman
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Kassem Sharif
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Scott Ehrenberg
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Uria Shani
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Yonatan Shneor Patt
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Nour Karra
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Abdulla Watad
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
| | - Howard Amital
- Department of Internal Medicine B & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Arnon Cohen
- Chief Physician's Office, Clalit Health Services Tel Aviv, Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
| | - Israel Dudkiewicz
- Rehabilitation Division, Sheba Medical Center, Tel-Hashomer, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
80
|
Relli-Dempsey V, Chavan B, Drozek D. The Complete Health Improvement Program and Physical Activity. Am J Lifestyle Med 2025; 19:288-293. [PMID: 39981550 PMCID: PMC11836576 DOI: 10.1177/15598276221089884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2025] Open
Abstract
BACKGROUND The Complete Health Improvement Program (CHIP) has demonstrated effectiveness in improving multiple cardiovascular disease risk factors. CHIP promotes physical activity, as well as a plant-based whole-food diet. The study objective is to evaluate the effectiveness of CHIP on improving levels of physical activity. METHODS CHIP participants had biomarkers measured at baseline and after the 11th session, consisting of level of physical activity, blood pressure (BP), body mass index (BMI), fasting blood sugar (FBS), and lipid panel. Pre and post data were analyzed using paired t-tests. RESULTS CHIP demonstrated significant increase in level of physical activity (P < .001) and decreased BMI, FBS, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides (all P < .001). Increased levels of physical activity correlated with decreased BMI (P < .001), but not with other biomarkers. CONCLUSION CHIP is effective in producing increased level of physical activity and improvement in multiple biomarkers. The increase in physical activity is correlated with decreased BMI.
Collapse
Affiliation(s)
| | - Bhakti Chavan
- Ohio University Heritage College of Osteopathic Medicine, Athens, OH, USA
| | - David Drozek
- Ohio University Heritage College of Osteopathic Medicine, Athens, OH, USA
| |
Collapse
|
81
|
Yang X, Yu Y, Hu G, Bai S, Wu J, Guo C. Causal effects of circulating immune cells on coronary atherosclerosis: Evidence from Mendelian randomization. Medicine (Baltimore) 2025; 104:e41361. [PMID: 39889170 PMCID: PMC11789883 DOI: 10.1097/md.0000000000041361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2024] [Revised: 12/19/2024] [Accepted: 01/08/2025] [Indexed: 02/02/2025] Open
Abstract
The role of circulating immune cells in coronary atherosclerosis remains unclear. This study aimed to assess the causal effects of various immune cells on coronary atherosclerosis using Mendelian randomization (MR). Circulating immune cell datasets were obtained from genome-wide association studies, and coronary atherosclerosis datasets were obtained from FinnGen. Single-nucleotide polymorphisms satisfying the assumptions of association, independence, and exclusivity were screened in the datasets and analyzed using MR, with inverse-variance weighted as the main method. Horizontal pleiotropy, heterogeneity, and sensitivity analyses were performed using the MR-Egger, Cochran Q, and leave-one-out analyses, respectively. The MR analysis showed that effector memory double negative (DN) (cluster of differentiation [CD]4-CD8-) %DN (odds ratio [OR]: 1.042, 95% confidence interval [CI]: 1.008-1.077, P = .014), CD4 on CD39+ CD4+ (OR: 1.027, 95% CI: 1.001-1.054, P = .040), C-X3-C motif chemokine receptor 1 on CD14+ CD16- monocytes (OR: 1.035, 95% CI: 1.010-1.060, P = .006), C-C chemokine receptor 7 on naive CD4+ (OR: 1.035, 95% CI: 1.006-1.076, P = .023), and immunoglobulin D- CD38- %lymphocytes (OR: 1.098, 95% CI: 1.016-1.187, P = .019) were associated with an increased genetic susceptibility to coronary atherosclerosis, with no horizontal pleiotropy (P ≥ .05). Cochran Q showed no heterogeneity (P ≥ .05), and the sensitivity analysis indicated that the results were robust. The MR analysis revealed various markers and immune cell subsets, including effector memory DN (CD4-CD8-) %DN, CD4 on CD39+ CD4+, C-X3-C motif chemokine receptor on CD14+ CD16- monocytes, C-C chemokine receptor 7 on naive CD4+, and IgD- CD38- %lymphocytes, associated with increased genetic susceptibility to coronary atherosclerosis. This provides a genetic explanation for the role of specific immune cells in inducing and exacerbating coronary artery disease and offers new ideas for the exploration of immune markers and immune-targeted drugs.
Collapse
Affiliation(s)
- Xinyu Yang
- Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
- School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Yunfeng Yu
- School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Gang Hu
- Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Siyang Bai
- School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Jingyi Wu
- The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Chenlu Guo
- Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
| |
Collapse
|
82
|
Capra ME, Aliverti V, Bellani AM, Berzieri M, Montani AG, Pisseri G, Sguerso T, Esposito S, Biasucci G. Breastfeeding and Non-Communicable Diseases: A Narrative Review. Nutrients 2025; 17:511. [PMID: 39940369 PMCID: PMC11819769 DOI: 10.3390/nu17030511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2025] [Revised: 01/27/2025] [Accepted: 01/28/2025] [Indexed: 02/16/2025] Open
Abstract
INTRODUCTION Breastfeeding plays a fundamental role in newborns' and infants' health. Breast milk's protective power against malnutrition and its positive effect on neurological and physical development are well established and are reflected in the policy statements of all major pediatric health entities. However, breastfeeding also plays an important role in the prevention of so-called non-communicable diseases, such as obesity, hypertension, dyslipidemia, and autoimmune diseases. METHODS This narrative review aims to analyze the effect of breastfeeding and breast milk on the development of non-communicable diseases, with a special focus on weight excess, dyslipidemia, allergy, and gastrointestinal diseases. This narrative review was carried out through three steps: executing the search, examining abstracts and full texts, and analyzing results. To achieve this, the databases PubMed, EMBASE, Scopus, ScienceDirect, Web of Science, and Google Scholar were explored to collect and select publications from 1990 to 2024 to find pertinent studies in line with this review's development. The search included randomized placebo-controlled trials, controlled clinical trials, double-blind, randomized controlled studies, and systematic reviews. A total of 104 manuscripts were ultimately included in the analysis. RESULTS Breastfeeding is associated with a decreased vulnerability to early viral infections or chronic inflammatory conditions during preschool years, a reduced incidence of weight excess, and likely lower cholesterol concentration, besides having a small protective effect against systolic blood hypertension. CONCLUSIONS Pediatricians must promote breastfeeding, support the mother-infant dyad, and consider breast milk as a real "health voucher" that can last lifelong. However, further studies are needed to better define the extent and duration of breastfeeding's protective power in this context.
Collapse
Affiliation(s)
- Maria Elena Capra
- Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy; (M.E.C.); (G.B.)
| | - Valentina Aliverti
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Arianna Maria Bellani
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Martina Berzieri
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Anna Giuseppina Montani
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Gianlorenzo Pisseri
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Tullia Sguerso
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Susanna Esposito
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| | - Giacomo Biasucci
- Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy; (M.E.C.); (G.B.)
- Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
| |
Collapse
|
83
|
Liu X, Wang M, Wen R, Zhu H, Xiao Y, He Q, Shi Y, Hong Z, Xu B. Following intravenous thrombolysis, the outcome of diabetes mellitus associated with acute ischemic stroke was predicted via machine learning. Front Pharmacol 2025; 16:1506771. [PMID: 39931692 PMCID: PMC11808246 DOI: 10.3389/fphar.2025.1506771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2024] [Accepted: 01/02/2025] [Indexed: 02/13/2025] Open
Abstract
This cohort study aimed to evaluate the prognostic outcomes of patients with acute ischemic stroke (AIS) and diabetes mellitus following intravenous thrombolysis, utilizing machine learning techniques. The analysis was conducted using data from Shenyang First People's Hospital, involving 3,478 AIS patients with diabetes who received thrombolytic therapy from January 2018 to December 2023, ultimately focusing on 1,314 patients after screening. The primary outcome measured was the 90-day Modified Rankin Scale (MRS). An 80/20 train-test split was implemented for model development and validation, employing various machine learning classifiers, including artificial neural networks (ANN), random forest (RF), XGBoost (XGB), and LASSO regression. Results indicated that the average accuracy of the XGB model was 0.7355 (±0.0307), outperforming the other models. Key predictors for prognosis post-thrombolysis included the National Institutes of Health Stroke Scale (NIHSS) and blood platelet count. The findings underscore the effectiveness of machine learning algorithms, particularly XGB, in predicting functional outcomes in diabetic AIS patients, providing clinicians with a valuable tool for treatment planning and improving patient outcome predictions based on receiver operating characteristic (ROC) analysis and accuracy assessments.
Collapse
Affiliation(s)
- Xiaoqing Liu
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Miaoran Wang
- The First Hospital of China Medical University, Shenyang, China
| | - Rui Wen
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Haoyue Zhu
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Ying Xiao
- Shenyang First People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Qian He
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Yangdi Shi
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Zhe Hong
- Shenyang First People’s Hospital, Shenyang Medical College, Shenyang, China
| | - Bing Xu
- Shenyang Tenth People’s Hospital, Shenyang Medical College, Shenyang, China
| |
Collapse
|
84
|
Wang W, Zhang L, Su G, Xiong F, Wu Y, Yu K, Yi Q, Sun P. Optimization of the acceleration of compressed sensing in whole-heart contrast-free coronary magnetic resonance angiography. J Cardiovasc Magn Reson 2025; 27:101845. [PMID: 39864742 PMCID: PMC11870249 DOI: 10.1016/j.jocmr.2025.101845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 01/03/2025] [Accepted: 01/21/2025] [Indexed: 01/28/2025] Open
Abstract
BACKGROUND This study aims to identify optimal acceleration factors (AFs) for compressed sensing (CS) technology to enhance its clinical application for suspected coronary artery disease (CAD) in whole-heart non-contrast coronary magnetic resonance angiography (CMRA). METHODS Two hundred and seventeen individuals with suspected CAD underwent whole-heart non-contrast CMRA on a 1.5T CMR scanner with CS AFs of 2, 4, and 6 (CS2, CS4, and CS6). Two radiologists independently and blindly scored the image quality. The overall image scores, coronary artery segment scores, signal-to-noise ratios (SNR), contrast-to-noise ratios (CNR), and scan times were compared. The scores for the left anterior descending coronary artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA) were assessed. Of the 217 patients, 37 (37/217, 17.1%) underwent x-ray coronary angiography (CAG). The images from CS2, CS4, and CS6 were evaluated by two radiologists blinded to CAG results to identify significant luminal narrowing. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. RESULTS The CS2 group exhibited higher overall scores, coronary artery segment scores, SNR, and CNR, but longer scan times compared to the CS4 and CS6 groups (overall score: 24.5 vs 22.0 vs 21.0, p < 0.001; SNR: 127 vs 112 vs 99, p < 0.001; CNRcor-fat: 118 vs 101 vs 84, p < 0.001; CNRcor-myo: 69.7 vs 62.8 vs 53.5, p < 0.001; scan time: 884 ± 308 s vs 473 ± 163 s vs 331 ± 146 s, p < 0.001). Proximal and middle segments received higher scores compared to their corresponding distal segments, and the RCA exhibited higher image quality than LAD and LCX in all groups (p < 0.05). In the subgroup analysis, 19 (19/37, 51.3%) were diagnosed with CAD by CAG. The sensitivity, specificity, PPV, NPV, and accuracy were as follows: CS2 (94.7%, 88.9%, 90.0%, 94.1%, and 91.9%), CS4 (89.5%, 94.4%, 94.4%, 89.5%, and 91.9%), and CS6 (89.5%, 66.7%, 73.9%, 85.7%, and 78.4%), respectively, in patient-based analysis. CONCLUSION Image quality showed a decreasing trend with increasing CS AFs, while scan time decreased in non-contrast CMRA. A scanning protocol using CS4 provided high-quality images with relatively short scan times and showed potential for detecting significant coronary stenosis, making it an optimal protocol for coronary magnetic resonance imaging.
Collapse
Affiliation(s)
- Weiwei Wang
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Longyan Zhang
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Guangzong Su
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Feng Xiong
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Yang Wu
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China.
| | - Ke Yu
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Qiaodan Yi
- Department of Magnetic Resonance Imaging, Wuhan Asia General Hospital, Wuhan, China
| | - Peng Sun
- Philips Healthcare, Beijing, China
| |
Collapse
|
85
|
Rytkin E, Zotova I, Passman R, Ardashev A, Trachiotis G, Efimov I, Knight BP. Consumer-grade wearable devices in arrhythmia diagnostics for clinicians: where we are and where we are going. J Interv Card Electrophysiol 2025:10.1007/s10840-025-01994-0. [PMID: 39863724 DOI: 10.1007/s10840-025-01994-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Accepted: 01/13/2025] [Indexed: 01/27/2025]
Abstract
Atrial arrhythmias, including atrial fibrillation (AF), are a major contributor to cardiovascular morbidity and mortality. Early detection and effective management are critical to mitigating adverse outcomes such as stroke, heart failure, and overall mortality. Wearable devices have emerged as promising tools for monitoring, detecting, and managing atrial arrhythmias near-continuously. This comprehensive analysis explores these wearable technologies' current role and capabilities for clinicians' daily practice. Despite challenges related to data accuracy, privacy, patient compliance, and integration with healthcare systems, ongoing advancements hold significant promise for the future. Continued research and development are essential to fully realize the potential of wearables in improving clinical outcomes for patients with atrial arrhythmias.
Collapse
Affiliation(s)
- Eric Rytkin
- Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA
| | - Irina Zotova
- Healthcare Department, State Budget Healthcare Institution "City Hospital #17" of Moscow, Moscow, Russia
| | - Rod Passman
- Division of Cardiology, Northwestern University, Chicago, IL, USA
| | - Andrey Ardashev
- Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E Superior Street, SQBRC Bldg, Room 11-532, Chicago, IL, 60611, USA.
| | - Gregory Trachiotis
- Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA
- Department of Surgery, The George Washington University Hospital, Washington, DC, USA
- Department of Biomedical Engineering, The George Washington University, Washington, DC, USA
| | - Igor Efimov
- Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA
| | - Bradley P Knight
- Division of Cardiology, Northwestern University, Chicago, IL, USA
| |
Collapse
|
86
|
Leyva-Vela B, Martínez-Olcina M, Asencio-Mas N, Vicente-Martínez M, Cuestas-Calero BJ, Matłosz P, Martínez-Rodríguez A. Integrated Multivariate Predictive Model of Body Composition and Lipid Profile for Cardiovascular Risk Assessment. J Clin Med 2025; 14:781. [PMID: 39941452 PMCID: PMC11818123 DOI: 10.3390/jcm14030781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2025] [Revised: 01/22/2025] [Accepted: 01/23/2025] [Indexed: 02/16/2025] Open
Abstract
(1) Background/Objectives: Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality globally, necessitating effective risk prediction strategies. This study was aimed at developing and validating a multivariate predictive model integrating body composition and lipid profile to assess cardiovascular risk in an adult population. (2) Methods: A cross-sectional analysis of 90 participants from the general Spanish population was conducted. Participants were classified into cardiovascular risk groups (low, medium, high) based on systolic blood pressure. (3) Results: Descriptive and multinomial logistic regression analyses revealed significant associations between cardiovascular risk and specific parameters, such as visceral fat, glucose levels, and waist-to-hip ratio. Visceral adiposity emerged as a strong predictor of high cardiovascular risk, highlighting its critical role in cardiovascular health. Glucose levels were also significantly associated with increased risk, underscoring the importance of metabolic health in cardiovascular outcomes. Contrary to expectations, lipid markers like cholesterol and triglycerides did not show significant variations across risk categories, suggesting that traditional lipid profiles may not fully capture cardiovascular risk in the study group. Waist-to-hip ratio showed significant associations with cardiovascular risk transitions, particularly between low and medium risk, emphasizing the importance of fat distribution patterns. (4) Conclusions: These findings suggest that body composition, particularly visceral fat, is a crucial determinant of cardiovascular risk, necessitating more personalized risk assessment approaches that move beyond traditional lipid markers.
Collapse
Affiliation(s)
- Belén Leyva-Vela
- Department of Health, Vinalopó University Hospital, 03293 Elche, Spain;
| | - Maria Martínez-Olcina
- Department of Analytical Chemistry, Nutrition and Food Science, University of Alicante, 03690 Alicante, Spain; (M.M.-O.); (N.A.-M.); (M.V.-M.); (A.M.-R.)
| | - Nuria Asencio-Mas
- Department of Analytical Chemistry, Nutrition and Food Science, University of Alicante, 03690 Alicante, Spain; (M.M.-O.); (N.A.-M.); (M.V.-M.); (A.M.-R.)
| | - Manuel Vicente-Martínez
- Department of Analytical Chemistry, Nutrition and Food Science, University of Alicante, 03690 Alicante, Spain; (M.M.-O.); (N.A.-M.); (M.V.-M.); (A.M.-R.)
| | | | - Piotr Matłosz
- Faculty of Physical Culture Sciences, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland
| | - Alejandro Martínez-Rodríguez
- Department of Analytical Chemistry, Nutrition and Food Science, University of Alicante, 03690 Alicante, Spain; (M.M.-O.); (N.A.-M.); (M.V.-M.); (A.M.-R.)
- Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain
| |
Collapse
|
87
|
Xie S, Peng S, Zhao L, Yang B, Qu Y, Tang X. A comprehensive analysis of stroke risk factors and development of a predictive model using machine learning approaches. Mol Genet Genomics 2025; 300:18. [PMID: 39853452 PMCID: PMC11762205 DOI: 10.1007/s00438-024-02217-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 12/15/2024] [Indexed: 01/26/2025]
Abstract
Stroke is a leading cause of death and disability globally, particularly in China. Identifying risk factors for stroke at an early stage is critical to improving patient outcomes and reducing the overall disease burden. However, the complexity of stroke risk factors requires advanced approaches for accurate prediction. The objective of this study is to identify key risk factors for stroke and develop a predictive model using machine learning techniques to enhance early detection and improve clinical decision-making. Data from the China Health and Retirement Longitudinal Study (2011-2020) were analyzed, classifying participants based on baseline characteristics. We evaluated correlations among 12 chronic diseases and applied machine learning algorithms to identify stroke-associated parameters. A dose-response relationship between these parameters and stroke was assessed using restricted cubic splines with Cox proportional hazards models. A refined predictive model, incorporating age, sex, and key risk factors, was developed. Stroke patients were significantly older (average age 69.03 years) and had a higher proportion of women (53%) compared to non-stroke individuals. Additionally, stroke patients were more likely to reside in rural areas, be unmarried, smoke, and suffer from various diseases. While the 12 chronic diseases were correlated (p < 0.05), the correlation coefficients were generally weak (r < 0.5). Machine learning identified nine parameters significantly associated with stroke risk: TyG-WC, WHtR, TyG-BMI, TyG, TMO, CysC, CREA, SBP, and HDL-C. Of these, TyG-WC, WHtR, TyG-BMI, TyG, CysC, CREA, and SBP exhibited a positive dose-response relationship with stroke risk. In contrast, TMO and HDL-C were associated with reduced stroke risk. In the fully adjusted model, elevated CysC (HR = 2.606, 95% CI 1.869-3.635), CREA (HR = 1.819, 95% CI 1.240-2.668), and SBP (HR = 1.008, 95% CI 1.003-1.012) were significantly associated with increased stroke risk, while higher HDL-C (HR = 0.989, 95% CI 0.984-0.995) and TMO (HR = 0.99995, 95% CI 0.99994-0.99997) were protective. A nomogram model incorporating age, sex, and the identified parameters demonstrated superior predictive accuracy, with a significantly higher Harrell's C-index compared to individual predictors. This study identifies several significant stroke risk factors and presents a predictive model that can enhance early detection of high-risk individuals. Among them, CREA, CysC, SBP, TyG-BMI, TyG, TyG-WC, and WHtR were positively associated with stroke risk, whereas TMO and HDL-C were opposite. This serves as a valuable decision-support resource for clinicians, facilitating more effective prevention and treatment strategies, ultimately improving patient outcomes.
Collapse
Affiliation(s)
- Songquan Xie
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China
| | - Shuting Peng
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China
| | - Long Zhao
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China
| | - Binbin Yang
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China
| | - Yukun Qu
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China
| | - Xiaoping Tang
- Neurosurgery Department of North Sichuan Medical College Affiliated Hospital, NanChong, 637000, Sichuan, China.
| |
Collapse
|
88
|
Strömberg S, Stomby A, Engvall J, Östgren CJ. Systematic Coronary Risk Evaluation 2 (SCORE2), arterial stiffness, and subclinical coronary atherosclerosis in a population-based study. Scand J Prim Health Care 2025:1-8. [PMID: 39853091 DOI: 10.1080/02813432.2025.2456948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Accepted: 01/15/2025] [Indexed: 01/26/2025] Open
Abstract
AIM To investigate the association between Systematic Coronary Risk Evaluation 2 (SCORE2) and subclinical damage in two vascular beds: atherosclerosis in the coronary arteries and aortic arterial stiffness, in a large population-based cohort without cardiovascular disease or diabetes. METHODS Design: A cross-sectional study based on Swedish CArdio Pulmonary bioImaging Study (SCAPIS) data. Study population: A population-based cohort of 3087 participants aged 50-64. OUTCOME Pulse Wave Velocity (PWV) was measured, and aortic arterial stiffness was defined as PWV≥ 10 m/s. Coronary artery calcium score (CACS) was determined by coronary computed tomography and clinically significant coronary calcification was defined as CACS > 100. RESULTS The prevalence of arterial stiffness was 6.6% in the low-moderate SCORE2 risk group, 31.0% in the high-risk group, and 53.3% in the very high-risk group. The prevalence of coronary calcification was 4.5%, 18.5% 23.0%, respectively. There was a modest overlap between arterial stiffness and coronary calcification in all SCORE2 risk groups. When comparing the high SCORE2 risk group with the low-moderate risk group, the Odds ratio (OR) was 6.4, 95% confidence interval (CI 5.1-8.0) for arterial stiffness and 4.8 (CI 3.7-6.3) for coronary calcification. When comparing the very high SCORE2 risk group to the low-moderate group, the OR was 16.2 (CI 11.3-23.1) for arterial stiffness and 6.4 (CI 4.2-9.7) for coronary calcification. CONCLUSION Our study shows that high cardiovascular risk according to SCORE2 is associated with increased arterial stiffness and significant coronary calcification in a population without prevalent cardiovascular disease or diabetes. This knowledge can be useful in primary care, where SCORE2 is frequently used as a risk prediction tool. The modest overlap between arterial stiffness and coronary calcification suggests that CACS and PWV describe different types of vascular damage.
Collapse
Affiliation(s)
- Susanna Strömberg
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
| | - Andreas Stomby
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
- Råslätts vårdcentral, Region Jönköping County, Jönköping, Sweden
| | - Jan Engvall
- Centre of Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| | - Carl Johan Östgren
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
- Centre of Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| |
Collapse
|
89
|
Li L, Zhong S, Ye J, Hu S, Xiong X, Chen G, Hu Z. Shenmai injection revives cardiac function in rats with hypertensive heart failure: involvement of microbial-host co-metabolism. BMC Complement Med Ther 2025; 25:24. [PMID: 39856640 PMCID: PMC11761217 DOI: 10.1186/s12906-024-04737-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 12/18/2024] [Indexed: 01/27/2025] Open
Abstract
Heart failure (HF) is a complex syndrome marked by considerable expenditures and elevated mortality and morbidity rates globally. Shenmai injection (SMI), a form of Traditional Chinese Medicine-based therapy, has demonstrated effectiveness in treating HF. Recent research suggests that Traditional Chinese Medicine (TCM) may induce beneficial changes in microbial-host co-metabolism, potentially providing cardiovascular protection. This study used a rat model of hypertensive heart failure (H-HF) to explore the mechanism of SMI. The possible compounds and key targets of SMI against H-HF were investigated using network pharmacology. The pharmacodynamics of SMI were validated using the H-HF animal model, with analysis of fecal gut microbiota integrating metabolomics and 16S rRNA sequencing. Metorigin metabolite traceability analysis and the MetaboAnalyst platform were utilized to explore the action mechanism. To evaluate changes in serum TMAO levels, targeted metabolomics was performed. Finally, the study looked at the intrinsic relationships among modifications in the intestinal flora, metabolite profile changes, and the targets of SMI compounds to clarify how they might be used to treat H-HF. According to metabolomics and 16S rRNA sequencing, by reestablishing homeostasis in the gut microbiota, SMI affects vital metabolic pathways, such as energy metabolism, amino acid metabolism, and bile acid metabolism. Increased serum TMAO levels were identified to be a risk factor for H-HF, and SMI was able to downregulate the levels of TMAO-related metabolites. Network pharmacology analysis identified 13 active components of SMI targeting 46 proteins, resulting in differential expression changes in 8 metabolites and 24 gut microbes. In conclusion, this study highlights the effectiveness of SMI in alleviating H-HF and its potential to modulate microbial-host co-metabolism. Through a comprehensive discussion of the interconnected relationships among the components, targets, metabolites, and gut microbiota, it provided fresh light on the therapeutic mechanism of SMI on H-HF.
Collapse
Affiliation(s)
- Lin Li
- The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
- Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Senjie Zhong
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Jiahao Ye
- The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Siyuan Hu
- The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Xiajun Xiong
- Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Guangyu Chen
- Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan, China
- Hunan Engineering Technology Research Center For Medicinal and Functional Food, Changsha, Hunan, China
| | - Zhixi Hu
- The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
- Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan, China.
| |
Collapse
|
90
|
Hassen M, Ebsa TK, Muhammed OS, Solomon T, Demessie MB, Wendie TF, Tesfaye NA, Gobezie MY. Patterns of beta-blocker use and dose optimization among ambulatory heart failure patients with reduced ejection fraction (HFrEF) attending public hospitals in Northeast Ethiopia: a multi-center cross-sectional study. BMC Cardiovasc Disord 2025; 25:43. [PMID: 39849374 PMCID: PMC11756068 DOI: 10.1186/s12872-025-04501-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Accepted: 01/15/2025] [Indexed: 01/25/2025] Open
Abstract
BACKGROUND Evidence-based beta-blockers are essential in managing heart failure with reduced ejection fraction (HFrEF) and are known to improve cardiovascular outcomes. Despite robust nascent guideline recommendations, studies indicate that beta-blockers are often underutilized or administered below target doses. This shivery issue is particularly relevant in Ethiopia, where comprehensive evaluations of beta-blocker utilization and dosing practices are limited. The Northeast region, specifically Dessie, remains underexplored in this context. OBJECTIVE This study aimed to evaluate the appropriate usage trend and dose optimization of beta-blockers among HFrEF patients attending ambulatory clinics of Dessie Comprehensive Specialized Hospital (DCSH) and Boru Meda General Hospital (BMH), Dessie, Ethiopia, 2024 G.C. METHODS A cross-sectional, multi-center study was conducted from February 1 to July 30, 2024, involving 200 randomly selected adult patients with confirmed HFrEF (120 from DCSH and 80 from BMH), who had at least 6-month regular follow-up visits at their respective ambulatory clinics. The study rigorously followed the latest (2022) American Heart Association (AHA) guideline recommendation. Patient's medical records was reviewed to gather the necessary data. A logistic regression analysis was performed to identify factors associated with beta-blocker use. Statistical significance was declared at p-value < 0.05. RESULTS Among the 200 patients, 88% were prescribed beta-blockers. About 15% of the patients were not receiving beta-blockers whereas they are indicated. Out of the total, 96.5% received guideline-recommended beta-blockers, with bisoprolol being the most common (65%), followed by metoprolol (29%) and carvedilol (3%). Only 13% of beta-blocker users were on optimal doses, with average daily doses of 27.9 mg for metoprolol succinate, 10.0 mg for carvedilol, and 4.8 mg for bisoprolol. Factors positively associated with beta-blocker use included Angiotensin Converting Enzyme Inhibitor use (AOR: 15.48, 95% CI: 2.11-113.54, p = 0.007), and taking multiple medications (AOR: 7.12, 95% CI: 1.54-33.02, p = 0.012), while ingestion of secondary prevention agents (AOR: 0.05, 95% CI: 0.01-0.98, p = 0.048) and male gender (AOR: 0.08, 95% CI: 0.01-0.47, p = 0.005) were negatively associated. Baseline ejection fraction of 25-40% (AOR: 5.44, 95% CI: 1.09-27.12, P = 0.039) was a sole predictor for sub-optimal beta-blocker use. CONCLUSION Although most patients with HFrEF were prescribed evidence-based beta-blockers, only a limited number reached the optimal dosing levels. It is crucial to align clinical practice with the latest guidelines, prioritize ongoing research, and enhance educational efforts for both healthcare providers and patients. By doing so, it is possible to significantly improve the effective utilization of beta-blockers, ultimately leading to better patient outcomes in this region.
Collapse
Affiliation(s)
- Minimize Hassen
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
| | - Tsehaynesh Kebede Ebsa
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| | - Oumer Sada Muhammed
- Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
| | - Tewodros Solomon
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| | - Mulat Belete Demessie
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| | - Teklehaimanot Fentie Wendie
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| | - Nuhamin Alemayehu Tesfaye
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| | - Mengistie Yirsaw Gobezie
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia
| |
Collapse
|
91
|
Ghasad PP, Vegivada JVS, Kamble VM, Bhurane AA, Santosh N, Sharma M, Tan RS, Rajendra Acharya U. A systematic review of automated prediction of sudden cardiac death using ECG signals. Physiol Meas 2025; 13:01TR01. [PMID: 39657316 DOI: 10.1088/1361-6579/ad9ce5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Accepted: 12/10/2024] [Indexed: 12/12/2024]
Abstract
Background. Sudden cardiac death (SCD) stands as a life-threatening cardiac event capable of swiftly claiming lives. It ranks prominently among the leading causes of global mortality, contributing to approximately 10% of deaths worldwide. The timely anticipation of SCD holds the promise of immediate life-saving interventions, such as cardiopulmonary resuscitation. However, recent strides in the realms of deep learning (DL), machine learning (ML), and artificial intelligence have ushered in fresh opportunities for the automation of SCD prediction using physiological signals. Researchers have devised numerous models to automatically predict SCD using a combination of diverse feature extraction techniques and classifiers. Methods: We conducted a thorough review of research publications ranging from 2011 to 2023, with a specific focus on the automated prediction of SCD. Traditionally, specialists utilize molecular biomarkers, symptoms, and 12-lead ECG recordings for SCD prediction. However, continuous patient monitoring by experts is impractical, and only a fraction of patients seeks help after experiencing symptoms. However, over the past two decades, ML techniques have emerged and evolved for this purpose. Importantly, since 2021, the studies we have scrutinized delve into a diverse array of ML and DL algorithms, encompassing K-nearest neighbors, support vector machines, decision trees, random forest, Naive Bayes, and convolutional neural networks as classifiers.Results. This literature review presents a comprehensive analysis of ML and DL models employed in predicting SCD. The analysis provided valuable information on the fundamental structure of cardiac fatalities, extracting relevant characteristics from electrocardiogram (ECG) and heart rate variability (HRV) signals, using databases, and evaluating classifier performance. The review offers a succinct yet thorough examination of automated SCD prediction methodologies, emphasizing current constraints and underscoring the necessity for further advancements. It serves as a valuable resource, providing valuable insights and outlining potential research directions for aspiring scholars in the domain of SCD prediction.Conclusions. In recent years, researchers have made substantial strides in the prediction of SCD by leveraging openly accessible databases such as the MIT-BIH SCD Holter and Normal Sinus Rhythm, which contains extensive 24 h recordings of SCD patients. These sophisticated methodologies have previously demonstrated the potential to achieve remarkable accuracy, reaching levels as high as 97%, and can forecast SCD events with a lead time of 30-70 min. Despite these promising outcomes, the quest for even greater accuracy and reliability persists. ML and DL methodologies have shown great promise, their performance is intrinsically linked to the volume of training data available. Most predictive models rely on small-scale databases, raising concerns about their applicability in real-world scenarios. Furthermore, these models predominantly utilize ECG and HRV signals, often overlooking the potential contributions of other physiological signals. Developing real-time, clinically applicable models also represents a critical avenue for further exploration in this field.
Collapse
Affiliation(s)
- Preeti P Ghasad
- Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India
| | - Jagath V S Vegivada
- Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India
| | - Vipin M Kamble
- Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India
| | - Ankit A Bhurane
- Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India
| | - Nikhil Santosh
- Department of Electrical and Computer Science Engineering, Institute of Infrastructure Technology Research and Management, Ahmedabad 380026, Gujarat, India
| | - Manish Sharma
- Department of Electrical and Computer Science Engineering, Institute of Infrastructure Technology Research and Management, Ahmedabad 380026, Gujarat, India
| | - Ru-San Tan
- National Heart Centre Singapore, Duke-NUS Medical School, Singapore, Singapore
| | - U Rajendra Acharya
- School of Mathematics, Physics and Computing, University of Southern Queensland, Springfield, Australia
- Centre for Health Research, University of Southern Queensland, Springfield, Australia
- Department of Biomedical Informatics and Medical Engineering, Asia University, Taichung, Taiwan
| |
Collapse
|
92
|
Rezaie-Kalamtari K, Norouzi Z, Salmanipour A, Mehrali H. Updates on CAD risk assessment: using the coronary artery calcium score in combination with traditional risk factors. Egypt Heart J 2025; 77:14. [PMID: 39847250 PMCID: PMC11757844 DOI: 10.1186/s43044-025-00608-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 01/07/2025] [Indexed: 01/24/2025] Open
Abstract
BACKGROUND Coronary artery disease (CAD) is the third leading cause of death worldwide, so prevention and early diagnosis play important roles to reduce mortality and morbidity. Traditional risk-score assessments were used to find the at-risk patients in order to prevent or early treatment of CAD. Adding imaging data to traditional risk-score systems will able us to find these patients more confidently and reduce the probable mismanagements. MAIN TEXT Measuring the vascular calcification by coronary artery calcium (CAC) score can prepare valuable data for this purpose. Using CAC became more popular in recent years. The most applicable method to evaluate CAC is Agatston scoring using computed tomography (CT) scanning. Patients are classified into several subgroups: no evidence of CAD (score 0), mild CAD (score 1-10), minimal CAD (score 11-100), moderate CAD (score 101-400), and severe CAD (score > 400) and higher than1000 as the extreme risk of CVD events. CONCLUSIONS CAC assessment was recommended in the patients older than 40 years old with CAD risk factors, the ones with stable angina, borderline-to-intermediate-risk group, etc. According to the results of the CAC the patients may be candidate for further evaluation for needing revascularization, medical treatment, or routine follow-up. Adding artificial intelligence (AI) to CAC will prepare more data and can increase the reliability of our approach to the patients promising a bright future to improve this technology.
Collapse
Affiliation(s)
- Kiara Rezaie-Kalamtari
- Rajaie Cardiovascular, Medical and Research Institute, Valiasr Ave, Hashemi Rafsanjani (Niayesh) Intersection, Tehran, Iran
| | - Zeinab Norouzi
- Rajaie Cardiovascular, Medical and Research Institute, Valiasr Ave, Hashemi Rafsanjani (Niayesh) Intersection, Tehran, Iran.
| | - Alireza Salmanipour
- Rajaie Cardiovascular, Medical and Research Institute, Valiasr Ave, Hashemi Rafsanjani (Niayesh) Intersection, Tehran, Iran
| | - Hossein Mehrali
- Rajaie Cardiovascular, Medical and Research Institute, Valiasr Ave, Hashemi Rafsanjani (Niayesh) Intersection, Tehran, Iran
- Rajaie Cardiovascular, Medical & Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
93
|
Scotti A, Sturla M, Echarte-Morales J, Ho EC, Millin A, Coisne A, Ludwig S, Leone PP, Rosiene J, Granada JF, Goldberg Y, Pu M, Jorde UP, Slipczuk L, Rodriguez CJ, Garcia MJ, Latib A. Burden of Valvular Heart Diseases in a Racially and Ethnically Diverse Population: The Bronx-Valve Registry. J Am Heart Assoc 2025; 14:e035378. [PMID: 39817520 DOI: 10.1161/jaha.124.035378] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Accepted: 10/01/2024] [Indexed: 01/18/2025]
Abstract
BACKGROUND Valvular heart disease (VHD) is a major focus of cardiovascular medicine, but limited data are available for racial and ethnic minorities. The aim was to assess the burden and clinical correlates of VHD in a highly diverse area of the United States. METHODS AND RESULTS Individuals with echocardiographic diagnosis of native VHD between January 2010 and December 2019 at a quaternary care health system of the Bronx (New York, USA) were included. Prevalence and correlates of VHD were assessed per each racial and ethnic group. From a total of 330 570 adult echocardiograms, 80 584 individuals were diagnosed with VHD and included in the final study population. Stratified by race and ethnicity, 38.0%, 23.2%, 2.1%, and 36.7% were non-Hispanic Black, non-Hispanic White, Asian, and Hispanic, respectively. The mean age was 67.7±16.3 years, with non-Hispanic Black, non-Hispanic Asian, and Hispanic individuals being younger and having a higher burden of comorbidities. The prevalence of VHD increased with age, irrespective of race or ethnicity. In people aged ≥75 years, tricuspid and mitral regurgitation were the most prevalent VHD (21.1% and 16.1%, respectively). Non-Hispanic White individuals more frequently had tricuspid regurgitation, mitral regurgitation, and multiple VHDs, but among those aged <65 years, these were more frequent in non-Hispanic Black individuals. CONCLUSIONS Our Bronx-Valve Registry illustrates that the burden of VHD is high, increases with age, and varies among racial and ethnic groups. When diagnosed with VHD, non-Hispanic Black, non-Hispanic Asian, and Hispanic individuals are younger and with a higher burden of comorbidities. Appropriate resources and strategies need to be implemented to minimize racial and ethnic disparities and promote equity in VHD diagnosis and cardiovascular risk factor management. REGISTRATION URL: https://clinicaltrials.gov. Unique Identifier: NCT05453526.
Collapse
Affiliation(s)
- Andrea Scotti
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Matteo Sturla
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Julio Echarte-Morales
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Edwin C Ho
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Antonella Millin
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Augustin Coisne
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Sebastian Ludwig
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Pier Pasquale Leone
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Joel Rosiene
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Juan F Granada
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
- Cardiovascular Research Foundation New York NY USA
| | - Ythan Goldberg
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Min Pu
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Ulrich P Jorde
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Leandro Slipczuk
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Carlos J Rodriguez
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Mario J Garcia
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| | - Azeem Latib
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA
| |
Collapse
|
94
|
Scaglione S, Di Chiara T, Daidone M, Tuttolomondo A. Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk. Nutrients 2025; 17:358. [PMID: 39861488 PMCID: PMC11768522 DOI: 10.3390/nu17020358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Revised: 12/14/2024] [Accepted: 01/06/2025] [Indexed: 01/27/2025] Open
Abstract
Metabolic syndrome is a cluster of risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia (intended as an increase in triglyceride levels and a reduction in HDL cholesterol levels), and elevated fasting glucose, that increase the risk of cardiovascular disease and type 2 diabetes. With the rising prevalence of metabolic syndrome, effective dietary interventions are essential in reducing these health risks. The Mediterranean diet, rich in fruits, vegetables, whole grains, legumes, nuts, and olive oil and moderate in fish and poultry, has shown promise in addressing metabolic syndrome and its associated components. This diet's anti-inflammatory and antioxidant properties, primarily due to its unsaturated fats, polyphenols, and fiber, have improved blood pressure, lipid levels, and insulin sensitivity. Adherence to the Mediterranean diet has been linked to reductions in central obesity and insulin resistance, both key elements in managing metabolic syndrome. Regarding lipid management, the Mediterranean diet lowers triglyceride levels and low-density lipoprotein (LDL) cholesterol while raising high-density lipoprotein (HDL) cholesterol, enhancing lipid profiles. It also helps regulate blood glucose levels, reducing the likelihood of developing type 2 diabetes. Additionally, the diet promotes weight loss and improves body composition, particularly by decreasing visceral fat, a primary driver of metabolic syndrome according to IDF classification. The Mediterranean diet offers a holistic approach to managing metabolic syndrome and reducing the risk of related chronic diseases. Its positive impact on metabolic health, combined with lifestyle changes like increased physical activity, provides a sustainable method for addressing the global burden of this syndrome. This review aimed to summarize the positive effects of the Mediterranean diet on the component of the metabolic syndrome with subsequent positive effects on cardiometabolic risk profile.
Collapse
Affiliation(s)
| | | | | | - Antonino Tuttolomondo
- Internal Medicine and Stroke Care Ward, Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (Promise) G. D’Alessandro, University of Palermo, 90127 Palermo, Italy; (S.S.); (T.D.C.); (M.D.)
| |
Collapse
|
95
|
Liu J, Huang Z, Luo F, Guo Y, Li Y, Wen J, Zhu J. Effect of metformin on the clinical outcomes of stroke in patients with diabetes: a systematic review and meta-analysis. BMJ Open 2025; 15:e092214. [PMID: 39819905 PMCID: PMC11751969 DOI: 10.1136/bmjopen-2024-092214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Accepted: 12/17/2024] [Indexed: 01/19/2025] Open
Abstract
OBJECTIVES Stroke is a major cause of death and disability globally, especially among diabetic patients. In this study, we aim to scrutinise the effects of metformin on the clinical outcomes of stroke in diabetic patients. DESIGN This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. DATA SOURCES PubMed, Embase and Web of Science databases were searched between their inception and 5 December 2023. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Studies investigating the effect of metformin on the clinical outcomes of stroke in patients with diabetes were included. DATA EXTRACTION AND SYNTHESIS The effect of metformin on the clinical outcomes of stroke in patients with diabetes was identified using combined ORs and 95% CIs. RESULTS A total of 11 studies involving 18 525 participants were included in this review. Pooled analysis has demonstrated that prestroke metformin use could reduce the probability of poor course after stroke by 34% in diabetes mellitus (DM) patients (OR=0.66, 95% CI: 0.61 to 0.72) and reduce the probability of death by 43% (OR=0.57, 95% CI: 0.51 to 0.64). CONCLUSIONS Prestroke metformin use is beneficial for the improvement of clinical outcomes in patients who had a stroke with DM, although the potential bias should be carefully considered. PROSPERO REGISTRATION NUMBER CRD42024496056.
Collapse
Affiliation(s)
- Jianyi Liu
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Zhihua Huang
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Fuqun Luo
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Yizhi Guo
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Yandeng Li
- Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Jun Wen
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| | - Jianming Zhu
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China
| |
Collapse
|
96
|
Iskandar M, Xiao Barbero M, Jaber M, Chen R, Gomez-Guevara R, Cruz E, Westerheide S. A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches. Cancers (Basel) 2025; 17:257. [PMID: 39858038 PMCID: PMC11764024 DOI: 10.3390/cancers17020257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Revised: 01/09/2025] [Accepted: 01/11/2025] [Indexed: 01/27/2025] Open
Abstract
BACKGROUND/OBJECTIVES As cells divide, telomeres shorten through a phenomenon known as telomere attrition, which leads to unavoidable senescence of cells. Unprotected DNA exponentially increases the odds of mutations, which can evolve into premature aging disorders and tumorigenesis. There has been growing academic and clinical interest in exploring this duality and developing optimal therapeutic strategies to combat telomere attrition in aging and cellular immortality in cancer. The purpose of this review is to provide an updated overview of telomere biology and therapeutic tactics to address aging and cancer. METHODS We used the Rayyan platform to review the PubMed database and examined the ClinicalTrial.gov registry to gain insight into clinical trials and their results. RESULTS Cancer cells activate telomerase or utilize alternative lengthening of telomeres to escape telomere shortening, leading to near immortality. Contrarily, normal cells experience telomeric erosion, contributing to premature aging disorders, such as Werner syndrome and Hutchinson-Gilford Progeria, and (2) aging-related diseases, such as neurodegenerative and cardiovascular diseases. CONCLUSIONS The literature presents several promising therapeutic approaches to potentially balance telomere maintenance in aging and shortening in cancer. This review highlights gaps in knowledge and points to the potential of these optimal interventions in preclinical and clinical studies to inform future research in cancer and aging.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sandy Westerheide
- Department of Molecular Biosciences, University of South Florida, 4202 East Fowler Avenue, ISA2015, Tampa, FL 33620, USA; (M.I.); (M.X.B.); (M.J.); (R.C.); (R.G.-G.); (E.C.)
| |
Collapse
|
97
|
Li G, Zhao Y, Peng Z, Zhao Y. Risk factors for the recurrence of atrial fibrillation after catheter ablation: a meta-analysis. Egypt Heart J 2025; 77:9. [PMID: 39804412 PMCID: PMC11729607 DOI: 10.1186/s43044-025-00605-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 01/02/2025] [Indexed: 01/16/2025] Open
Abstract
BACKGROUND The rate at which atrial fibrillation (AF) patients experience a return of symptoms after catheter ablation is significant, and there are multiple risk factors involved. This research intends to perform a meta-analysis to explore the risk factors connected to the recurrence of AF in patients following catheter ablation. METHODS The PubMed, Cochrane Library, WOS, Embase, SinoMed, CNKI, Wanfang, and VIP databases were explored for studies from January 1, 2000 to August 10, 2021, and research meeting the established inclusion requirements was chosen. Two authors separately gathered details regarding the study structure. The strength of the link between various risk factors and AF returning after CA was evaluated using odds ratios. All statistical evaluations were conducted with RevMan5.3 software. RESULTS In total, 44 articles and 62,674 patients were included. The OR for AF recurrence in patients with diabetes was 2.04 compared with the reference group (95% CI 1.51-2.76, p < 0.00001); that of lower left ventricular ejection fraction was 1.38 (95% CI 1.25-1.52, p < 0.00001); that of female was 1.34 (95% CI 1.18-1.52, p < 0.00001); that of increased age was 1.03 (95% CI 1.02-1.04, p < 0.00001); that of persistent AF was 1.72 (95% CI 1.58-1.87, p < 0.00001); that of AF duration over 2 years was 1.17 (95% CI 1.08-1.26, p < 0.00001); that of increased left atrial diameter (LAD) was 1.12 (95% CI 1.08-1.17, p < 0.00001); that of larger left atrial volume index (LAVi) was 1.02 (95% CI 1.01-1.03, p < 0.00001); that of higher hs-CRP was 1.19 (95% CI 1.04-1.36, p = 0.04); that of early recurrence (ER) was 3.22 (95% CI 2.74-3.77, p < 0.00001); and that of long ablation duration was 1.00 (95% CI 0.98-1.02, p = 0.72). Heterogeneity and slight publication bias were observed for each factor. CONCLUSIONS Evidence indicates that diabetes, low left ventricular ejection fraction, being female, older age, longer duration of atrial fibrillation, elevated high-sensitivity C-reactive protein levels, large left atrial dimension, large left atrial volume index, persistent atrial fibrillation, and exercise rehabilitation are factors that increase the chances of getting atrial fibrillation again after catheter ablation. However, the length of the ablation procedure does not relate to the recurrence of AF.
Collapse
Affiliation(s)
- Gonghao Li
- Department of Cardiology, Lianyungang No 1 People's Hospital, No. 6 East Zhenhua Road, Haizhou District, Lianyungang, 222061, Jiangsu, China.
- The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, China.
| | - Yanli Zhao
- Department of Cardiology, Lianyungang No 1 People's Hospital, No. 6 East Zhenhua Road, Haizhou District, Lianyungang, 222061, Jiangsu, China
| | - Zhongxing Peng
- Department of Cardiology, Lianyungang No 1 People's Hospital, No. 6 East Zhenhua Road, Haizhou District, Lianyungang, 222061, Jiangsu, China
| | - Yunfeng Zhao
- Department of Cardiology, Lianyungang No 1 People's Hospital, No. 6 East Zhenhua Road, Haizhou District, Lianyungang, 222061, Jiangsu, China
| |
Collapse
|
98
|
Li X, Zhao C, Liu M, Zhao W, Pan H, Wang D. Sociodemographic index-age differences in the global prevalence of cardiovascular diseases, 1990-2019: a population-based study. Arch Public Health 2025; 83:2. [PMID: 39780273 PMCID: PMC11715713 DOI: 10.1186/s13690-024-01454-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Accepted: 11/18/2024] [Indexed: 01/11/2025] Open
Abstract
BACKGROUND This study aims to assess the global burden and trends in cardiovascular diseases (CVDs) prevalence, stratified by sociodemographic index (SDI) categories and age groups, across 204 countries and territories. METHODS Utilizing data from the Global Burden of Disease Study 2019, this study analyzed trends in the age-standardized prevalence rate of overall and type-specific CVDs, including rheumatic heart disease, ischemic heart disease, stroke, hypertensive heart disease, non-rheumatic valvular heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, peripheral artery disease, endocarditis, and other cardiovascular and circulatory diseases. Age-standardized prevalence rates were stratified by SDI categories (low, low-middle, middle, high-middle, and high) and age groups (0-14, 15-49, 50-69, and ≥ 70 years). The corresponding average annual percentage change was calculated to assess temporal trends. RESULTS From 1990 to 2019, the global age-standardized prevalence rate per 100,000 population for CVD decreased from 6728.04 (95% UI 6394.55 to 7059.66) to 6431.57 (95% UI 6109.95 to 6759.8), with an average annual percent change of -0.15% (95% CI -0.17 to -0.13). When stratified by SDI category, the age-standardized prevalence rate of CVD decreased significantly in high-middle and high SDI countries but increased in middle, low-middle, and low SDI countries. By age group, the age-standardized prevalence rate of CVD declined in the 50-69 and ≥ 70 years groups but increased in the 0-14 and 15-49 years groups. SDI levels were negatively associated with faster increases in the age-standardized prevalence rate of CVD across all ages and age groups. Low SDI countries consistently showed the highest age-standardized prevalence rates of CVD in the younger age groups (0-14 and 15-49 years), while high-middle SDI countries had the highest rates in the older age groups (50-69 and ≥ 70 years). The age-standardized prevalence rate of CVD was negatively associated with SDI levels in the 0-14 and 15-49 years groups and positively associated with SDI levels in the 50-69 and ≥ 70 years groups. Type-specific CVDs such as rheumatic heart disease, other cardiovascular and circulatory diseases, non-rheumatic valvular heart disease, and hypertensive heart disease showed increased age-standardized prevalence rates from 1990 to 2019. CONCLUSIONS This study highlights significant disparities in CVD prevalence across sociodemographic and age groups. While the global prevalence of CVD has generally decreased, the rise in CVD prevalence in lower SDI countries and younger populations calls for tailored intervention strategies. Addressing these disparities is crucial to mitigating the growing burden of CVD and promoting cardiovascular health on a global scale.
Collapse
Affiliation(s)
- Xunliang Li
- Department of Nephrology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Channa Zhao
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China
| | - Mengqian Liu
- Department of Nephrology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Wenman Zhao
- Department of Nephrology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Haifeng Pan
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
| | - Deguang Wang
- Department of Nephrology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
| |
Collapse
|
99
|
Franz K, Markó L, Mähler A, Chakaroun R, Heinitz S, Schlögl H, Sacher J, Steckhan N, Dechend R, Adams N, Andersen M, Glintborg D, Viehweger M, Bahr LS, Forslund-Startceva SK. Sex hormone-dependent host-microbiome interactions and cardiovascular risk (XCVD): design of a longitudinal multi-omics cohort study. BMJ Open 2025; 15:e087982. [PMID: 39788783 PMCID: PMC11751863 DOI: 10.1136/bmjopen-2024-087982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Accepted: 12/23/2024] [Indexed: 01/12/2025] Open
Abstract
INTRODUCTION Cardiovascular diseases (CVDs) present differently in women and men, influenced by host-microbiome interactions. The roles of sex hormones in CVD outcomes and gut microbiome in modifying these effects are poorly understood. The XCVD study examines gut microbiome mediation of sex hormone effects on CVD risk markers by observing transgender participants undergoing gender-affirming hormone therapy (GAHT), with findings expected to extrapolate to cisgender populations. METHODS AND ANALYSES This observational, longitudinal cohort study includes baseline, 1- and 2-year follow-ups with transgender participants beginning GAHT. It involves comprehensive phenotyping and microbiome genotyping, integrating computational analyses of high-dimensional data. Microbial diversity will be assessed using gut, skin, and oral samples via 16S rRNA and shotgun metagenomic sequencing of gut samples. Blood measurements will include sex hormones, CVD risk markers, cardiometabolic parameters, cytokines, and immune cell counts. Hair samples will be analysed for cortisol. Participants will complete online questionnaires on physical activity, mental health, stress, quality of life, fatigue, sleep, pain, and gender dysphoria, tracking medication use and diet to control for confounders. Statistical analyses will integrate phenomic, lifestyle, and multi-omic data to model health effects, testing gut microbiome mediation of CVD risk as the endocrine environment shifts between that typical for cisgender men to women and vice versa. ETHICS AND DISSEMINATION The study adheres to Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the Charité Ethical Committee (EA1/339/21). Signed informed consent will be obtained. Results will be published in peer-reviewed journals and conferences and shared as accessible summaries for participants, community groups, and the public, with participants able to view their data securely after public and patient involvement review for accessibility. TRIAL REGISTRATION NUMBER The XCVD study was registered on ClinicalTrials.gov (NCT05334888) as 'Sex-differential host-microbiome CVD risk - a longitudinal cohort approach (XCVD)" on 4 April 2022. Data set link can be found at https://classic. CLINICALTRIALS gov/ct2/show/NCT05334888.
Collapse
Affiliation(s)
- Kristina Franz
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, DZHK, Berlin, Germany
- Deutsches Herzzentrum der Charité - Medical Heart Center of Charité and German Heart Institute Berlin, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Lajos Markó
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, DZHK, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Anja Mähler
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Rima Chakaroun
- Medical Department III Endocrinology Nephrology Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
- Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg Wallenberg Laboratory for Cardiovascular and Metabolic Research, Goteborg, Sweden
| | - Sascha Heinitz
- Medical Department III Endocrinology Nephrology Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Haiko Schlögl
- Medical Department III Endocrinology Nephrology Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
- HI-MAG, Helmholtz Institute for Metabolic Obesity and Vascular Research, Leipzig, Germany
| | - Julia Sacher
- Clinic for Cognitive Neurology, University of Leipzig Medical Center, and Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Max-Planck-Institut fur molekulare Physiologie, Dortmund, Germany
| | - Nico Steckhan
- Digital Health - Connected Healthcare, Hasso Plattner Institute, University of Potsdam, Potsdam, Germany
| | - Ralf Dechend
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, DZHK, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Helios Clinic Berlin-Buch, Berlin, Germany
| | - Noah Adams
- University of Toronto, Toronto, Ontario, Canada
- Center for Applied Transgender Studies (CATS), Chicago, Illinois, USA
- Transgender Professional Association for Transgender Health, TPATH, Toronto, Ontario, Canada
| | - Marianne Andersen
- Department of Endocrinology, Odense Universitetshospital, Odense, Denmark
- Institute of Clinical Research, University of Southern Denmark, Odense, Syddanmark, Denmark
| | - Dorte Glintborg
- Institute of Clinical Research, University of Southern Denmark, Odense, Syddanmark, Denmark
- Body Identity Clinic, Odense Universitetshospital Endokrinologisk Afdeling M, Odense, Denmark
| | | | - Lina Samira Bahr
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, DZHK, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Sofia Kirke Forslund-Startceva
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, DZHK, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Transgender Professional Association for Transgender Health, TPATH, Toronto, Ontario, Canada
- European Molecular Biology Laboratory Structural and Computational Biology Unit, Heidelberg, Baden-Württemberg, Germany
| |
Collapse
|
100
|
Fu T, Zhang W, Guo R, He S, Yu S, Wang H, Zhang Y, Wu Y. Inclusion of hypocretin-1 improved performance of poor sleep quality prediction for elderly patients with acute ischemic stroke: a prospective cohort study. Front Aging Neurosci 2025; 16:1509846. [PMID: 39839304 PMCID: PMC11747788 DOI: 10.3389/fnagi.2024.1509846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Accepted: 12/12/2024] [Indexed: 01/23/2025] Open
Abstract
Background Hypocretin-1 is a vital neurotransmitter in regulating the sleep-wake cycle and provides neuroprotection against cerebral ischemia. We aims to develop a poor sleep quality predictive model for elderly population with acute ischemic stroke. Methods A total of 183 consecutively elderly patients were included in the prospective cohort study. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Cerebrospinal fluid samples were taken within 24 h of acute ischemic stroke onset. After selecting optimal predictors via univariate analysis and bootstrapped stepwise logistic regression, the predictive model was developed. The models were internally validated and evaluated comprehensively via discrimination, calibration, and clinical utility. Results The prevalence of poor sleep (PSQI >7) was 64.5% among elderly individuals experiencing acute ischemic stroke. The study developed a predictive model using hypocretin-1, hypertension, stroke history, the National Institutes of Health Stroke score, and depression. Adding hypocretin-1 (as continuous variable) significantly improved the model performance greatly, as the area under the receiver operating characteristic curve increased from 0.799 to 0.845 (p < 0.001). The optimal cutoff value for hypocretin-1 was 74.94 pg/mL. Adding hypocretin-1 (as binary variable) significantly improved the model performance greatly, as the AUC increased from 0.799 to 0.857 (p < 0.001). Conclusion Reduced cerebrospinal fluid levels of hypocretin-1 at admission were an independent poor sleep quality predictor and the model demonstrated superior performance. The combination of hypocretin-1 could offer valuable prognostic information for post-stroke sleep quality in elderly patients with acute ischemic stroke.
Collapse
Affiliation(s)
- Ting Fu
- School of Nursing, Capital Medical University, Beijing, China
| | - Weiwei Zhang
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
| | - Rongrong Guo
- School of Nursing, Capital Medical University, Beijing, China
| | - Shuang He
- Department of Stroke Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
| | - Saiying Yu
- School of Nursing, Capital Medical University, Beijing, China
| | - Huiying Wang
- School of Nursing, Capital Medical University, Beijing, China
| | - Yunfeng Zhang
- Department of Neurology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
| | - Ying Wu
- School of Nursing, Capital Medical University, Beijing, China
| |
Collapse
|